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Uncontrolled cell growth and cell division are central to the process of tumorigenesis and a 
number of gene expression signatures have been developed based on genes that are 
involved in the cell cycle. Notably, gene expression signatures are used extensively in 
breast cancer research to examine the disease at a molecular level to describe tumour 
progression, treatment response and patients’ survival. 
The subject of this thesis is to explore the potential prognostic capacity of gene expression 
signatures in breast cancer and additionally, determine the prognostic capacity of a 
transcriptomic cell cycle activity (CCS) signature within variety of cancer types. 
 
Several breast cancer gene expression signatures have emerged and been validated over the 
past two decades in large retrospective clinical trials. Although the clinical impact of these 
signatures has been clearly demonstrated, breast cancer therapeutic guidelines are still 
established on the basis of immunohistochemical markers (IHC) such as estrogen (ER), 
progesterone (PR), human epidermal growth factor 2 (HER2) and the proliferation marker 
Ki67. In Study I, the additional prognostic information derived from the combination of 
gene expression signatures and IHC/Ki67 was investigated in two Swedish breast cancer 
cohorts. Cohort I is comprised of 621 individuals with primary breast cancer tumours 
diagnosed between 1997 and 2005 in Stockholm region of Sweden. Cohort II consists of 
484 individuals with primary breast tumours who diagnosed and received primary therapy 
in the Uppsala region of Sweden between 1987 and 1989. In Cohort I, Recurrence score 
(RS) and PAM50 gene expression signatures added prognostic information beyond Ki67 
and IHC subtypes while only IHC subtypes provided additional prognostic information to 
all gene expression signatures with the exception of PAM50 gene signature in this cohort. 
Similar results were observed in Cohort II.  
 
The ability of gene expression signatures to provide prognostic and treatment predictive 
information has been tested in primary breast tumours; however, their capability to provide 
similar information in the metastatic breast cancer (MBC) patients has not been 
investigated.  In Study II, the prognostic capacity of gene expression signatures in breast 
cancer was evaluated in the metastatic setting in a Swedish multicenter randomized clinical 
trial known as “TEX” with 304 patients diagnosed with advanced locoregional or distant 
breast cancer relapse. A large number of tumours were classified into intermediate or high-
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risk groups by all gene expression signatures. PAM50 was the only gene expression 
signature that provided prognostic information from lymph node (LN) metastases. 
 
In Study III, the prognostic and treatment-specific potential of CCND1 amplification was 
assessed in two breast cancer cohorts with 1965 and 340 patients, respectively. In the 
combined cohort, patients with CCND1-amplified tumours show worse survival in 
ER+/HER2-/LN-, luminal A and luminal B subtypes. Moreover, luminal A subtype with 
CCND1-amplified tumours shared similar gene expression changes with and luminal B 
subtype. 
 
In Study IV, the DNA mutations and chromosome arm-level aneuploidy within tumours 
with different cell cycle activity (CCS) were explored. We showed that cell cycle activity 
varied broadly among and within different cancer types. Two well-known oncogenes (TP53 
and PIK3CA) exhibit the highest rate of mutations within different CCS groups. 
Furthermore, chromosomal arm level aberrations present in all CCS groups with a higher 
number of gains in 7p, 20q whereas deletions were more frequent within 17p and 8p arms. 
In the survival analysis, patients with higher CCS tumours show worse Progression-free 
interval relative to low and intermediate CCS groups. 
 
In conclusions, we have shown that PAM50 and RS gene expression signatures can add 
prognostic information to Ki67 and IHC subtypes; however, IHC subtypes did not add any 
prognostic information to PAM50 signature. Moreover, PAM50 gene expression signature 
can provide prognostic information from LN metastases in MBC patients. Additionally, 
CCND1 gene amplification has the potential to stratify patients with worse survival 
outcome within good-prognosis luminal A subtype tumours. Finally, we have demonstrated 
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 HALLMARKS OF CANCER 
 
Cancer is a series of diseases caused by uncontrolled cell growth and cell division 
with the potential to spread to the other organs in the body. There are more than 200 known 
types of cancer. The steps leading to the transformation of normal cells to cancer cells, and 
their subsequent development and progression to a metastatic lesion are best described by 
the landmark “hallmarks of cancer” publication by Hannan and Weinberg1. The authors 
describe six main steps governing disease progression including sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis1. In the most 
recent update by the same authors, four new hallmarks were added2: deregulating cell 
energetics, avoiding immune destruction, genome instability and mutation, tumour-
promoting inflammation. Whilst the authors note that cancers develop as an abnormal mass 
of tissue known as a tumour or neoplasm in a solid or fluid form, not all tumours are 
cancerous and benign (not cancerous), premalignant (precancerous) and malignant 
(cancerous) tumours have also been described3, 4.  
 
 THE CELL CYCLE 
 
In a normal cell, the process of duplicating DNA in the chromosomes and segregating the 
copies into genetically identical daughter cells is the basic function of the cell cycle5. The 
cell cycle in Eukaryotes is comprised of 4 distinct phases, each of which is shown in Figure 
1. G1 phase: In proliferative cells the cell cycle starts with the “G1” or Gap1 phase where 
cells prepare for DNA replication in the S phase. In contrast, in highly differentiated cells, 
cell cycle begins from “G0” or Gap0 phase where cells are quiescent (non-proliferative). S 
phase: The next phase is known as the synthesis or “S” phase, where the DNA material of 
the cell is replicated. G2 phase: The “G2” or Gap2 phase resides between the S and M 
phase of the cell cycle and is where cells prepare for mitosis - the process where cell 
division, occurs. M phase: The “M” or mitosis phase is the final phase of the cell cycle 
when the replicated DNA is divided into two nuclei5, 6(Figure 1), after which the cell 




1.2.1 Cyclins and Regulation of the cell cycle 
 
Our knowledge on the cell cycle and cell cycle regulators has expanded over the 
past three decades. The cell division cycle (CDC) genes and cyclins were identified in yeast 
by Hartwell et al. for the first time7 and following up on this discovery, Lee and Nurse et al. 
discovered a key regulator gene of the cell cycle “cdc2”. Then, by isolating the 
corresponding cell cycle control genes in humans they demonstrated that these genes 
belong to the family of cyclin dependent kinases (CDKs)8. In 1982, Evans et al. discovered 
Cyclins in sea urchins and demonstrated their interaction with CDKs9. Hitherto, several 
cyclins and CDKs have been discovered. Cyclins in association with their binding partners 
CDKs govern multiple events including the progression of the cell cycle, cellular growth 
and DNA replication processes at different check-points of the cell cycle 5, 6.  
 
Cyclin D: In the G1 phase of the cell cycle, Cyclin D1, D2 and D3 in combination with 
CDK4 and 6 phosphorylates retinoblastoma-associated protein (RB1) and retinoblastoma-
like protein 1 and 3 (RBL1, RBL3); this process triggers Cyclin E1 and E2 expression and 
further phosphorylation of RB1, RBL and RBL3.  
Figure 1. Schematic view of different phases of the cell cycle, 
cell cycle checkpoints and key components of the cell cycle 
regulation. 




Cyclin E: E-type Cyclins are required in the early stages of DNA synthesis and the 
combination CDK2 and Cyclin E regulate G1 to S phase transition of the cell cycle10, 11.  
Cyclin A: In the G2 phase of the cell cycle, CDK2-Cyclin A2 complex initiates transition 
of S phase to mitosis in the M phase10, 11.  
Cyclin B: Cyclin B has an essential role for the progression of M phase in the cell cycle. 
Cyclin B-CDK1 complex initiates transition of G2 to M phase and the subsequent 
degradation of Cyclin B is necessary for the cell to exit the cell cycle.  
 
Given the central role of Cyclins in regulating the cell cycle and by extension, cell 
proliferation, it is unsurprising that perturbations effecting the function and expression of 
Cyclin D6, 12, E13, 14, A15, 16, B17, 18, have all been linked to cancer. A schematic view of the 
cell cycle and involvement of Cyclins-CDKs complexes is shown in Figure 1. 
 
1.2.2 Cell cycle checkpoints 
 
The cell cycle machinery is highly regulated by several Onco- and tumour suppressor genes 
and other key regulatory elements such as the Cyclins-CDK complexes. There are three 
main restriction/checkpoints that occur during the cell cycle in order to stop its progression 
when it is not permitted19. These checkpoints take place at G1/S, G2 and M phases of the 
cell cycle (Figure 1). 
 
G1/S checkpoint: In the G1/S checkpoint, the DNA bases will be examined for damages 
and prevented from being copied if any errors are recognized. After error identification, the 
DNA damage or stress signals have to be repaired in order to let cells pass this 
checkpoint19. These mechanisms are mediated by the ataxia telangiectasia mutated (ATM), 
ataxia telangiectasia and Rad3-related (ATR) protein kinases and their downstream targets 
checkpoint kinases (CHK) 1/219. 
 
G2 checkpoint: In the G2 checkpoint, DNA strands are checked for any damages or breaks 
after the replication in the S phase. Any mistakes in the DNA replication detected by the 
checkpoint mechanisms at this point will induce cell cycle arrest. All the errors should be 




M checkpoint: During the M phase of the cell cycle, chromosome segregation happens with 
the help of Kinetochore microtubules (MT)20. MTs will be attached to the center of 
chromosomes (centromeres), pulling them to the polar ends of the cell. At this checkpoint, 
all the prerequisites for chromosomal division will be checked ensuring proper progression 
of the M phase19. The M checkpoint prevents mitosis if the chromosomes are not properly 
attached to MTs or not correctly aligned with mitotic spindles19.  
 
In the case of a damage cell evading restriction points, a tumour suppressor gene (P53) can 
activate the CDK inhibitor 1 gene (P21) subsequently preventing Cyclin and CDKs from 
forming Cyclin-CDK complexes21. If DNA damages in the genome are not repairable, P53 
induces apoptosis by interacting with proapoptotic proteins such as B-cell lymphoma (Bcl)-
2 protein family22.  
 
 
1.2.3 Cyclin D1 
 
Cyclin D1 along with its binding partners CDK4 and CDK6 promotes progression 
from G1 to S phase of the cell cycle via the mechanism that has described in the previous 
section. In addition to the involvement of Cyclin D1-CDK4/6 complex in the cell cycle 
machinery, this complex contributes to several cellular functions including cell migration, 
cell growth, cell adhesion, cytoskeletal modeling and centrosome duplication as shown in 
Figure 2A6, 23–26. 
Furthermore, Cyclin D1 is independently associated in DNA repair and sequestration of 
CDK inhibitors promoting CDK2 activity. Subsequently, CDK2 binds to Cyclin E and 
forms the Cyclin E-CDK2 complex27–29. Cyclin D1 can also bind to P21 and P27 in the 
absence of CDK4/6, thus triggering the DNA damage response independently. Cyclin D1 is 
also involved in adipogenesis by interacting with transcription factors such as estrogen 










Different genetic alterations in CCND1 oncogene have been frequently observed in several 
cancer types (Figure 3). The overexpression and amplification of this gene have been 
reported to be correlated to poor prognosis in breast cancer and lung cancer patients31–34. 
Despite good correlation between CCND1 gene amplification and Cyclin D1 protein 
expression, the overexpression of Cyclin D1 protein has contradictory impact on the 
prognosis of breast cancer patients. Some studies have shown its association with good 
prognosis in breast cancer patients35, 36 whereas others have reported poor prognosis in 
these patients37, 38. Ortiz et al. have demonstrated that in a subgroup of patients with 
luminal A tumours, higher nuclear protein expression is associated with shorter disease-free 
B 
A 
Figure 2. Functions of Cyclin D1 in (A) CDK-dependent and (B) CDK-independent 
manner (Musgrove et al. 2011) 
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survival (DFS) (P = 0.029)37. Moreover, in a retrospective study with primary breast cancer 
tumours, patients whose tumours exhibited overexpression of Cyclin D1 protein have 
















Figure 3. Frequency of genetic alterations in CCND1 across different cancer types. Mutations, 
Gene amplification and deletions are shown in green, red and blue respectively. 
ACC = Adenocarcinoma, LGG = Brain Lower Grade Glioma, GBM = Glioblastoma multiforme, 
NSCLC = non-small cell lung carcinoma; taken from cBioPortal (Gao et al. Sci. Signal. 2013 & 
Cerami et al. Cancer Discov. 2012) 
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2 BREAST CANCER 
 BIOLOGY OF THE FEMALE BREAST 
 
The female breast is a very complex organ, comprised of adipose tissue with fibrous, 
connective tissues, nerves, lymph and blood vessels, as well as mammary glands which 
form around 15-20 lobules in a normal breast. During the process of breast tumorigenesis 
mammary cells undergo several genomic aberrations to bypass the cell cycle check points 
and tissue homeostasis. Interruption in cellular mechanisms such as cell migration or 
suppression of the immune system and genetic instability contribute to the development of 
cancer and metastatic progression. Several oncogenes including estrogen receptor 1 (ESR1), 
progesterone receptor (PGR), Human epidermal receptor gene 2 (ERBB2), Breast Cancer 
Gene (BRCA) 1 and 2 have been shown to be important prognostic and response to 
therapies predictors for breast cancer patients. More detailed information regarding the 




Breast cancer is the most common cancer diagnosed in women (24.2%) with more than 2 
million incidences each year39.  According to World Health Organization (WHO) around 
627,000 women died from breast cancer in 2018 that is around 15% of all cancer related 
deaths among women (Figure 4)39.  
Figure 4. Estimated number of cancer-related deaths in 2018 
among women around the world. (GLOBOCAN2018) 
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However, due to better prognosis, breast cancer is only the fifth leading cause of death in 
the world40.  As shown in Figure 5A, despite a higher rate of breast cancer incidents in 
developed countries the survival rate is around 80% in North America and Europe. 
Whereas in less-developed countries the survival rate is significantly lower (40%), due to 
late detection of the disease, diagnosis and treatments in those regions39. Although 
incidence of breast cancer has increased exponentially in Scandiavian countries after 1960s, 
the number of breast cancer-related deaths has decreased in recent years; owing the 
population-based mammography screening in combination with adjuvant chemotherapy, 
endocrine and targeted therapies in the region (Figure 5B)41. According to the latest report 
from Swedish National Board of Health and Welfare (Socialstyrelsen)42, around 5% of total 
7,500 women who were diagnosed with breast cancer in 2016 died because of the disease43.   
Figure 5. Age standardized incidence and mortality rates of breast cancer (A) 
around the world/per 100000 cases (WHO) and (B) in Scandinavian countries* 
between 1950-2015 (Nordic cancer registries 2018). *Incidences: Denmark in 
Red, Norway in Green, Sweden in Blue; Mortality rate: Denmark in Orange, 





 RISK FACTORS 
 
Cancer is also called a disease of ageing which leads to the malfunction of multiple 
cells and tissues. Apart from age, several other factors mostly associated with lifestyle have 
been identified as risk factors for cancer development including smoking, alcohol 
consumption, physical activities and body weight44–46. Family history of cancer and viral 
infections are also considered as risk factors in some cancer types47. However, some factors 
are directly associated with progression of specific cancer types. Risk factors for breast 
cancer include an early menstrual period, late or no pregnancies, menopause after age of 55, 
having a dense breast, using combination hormonal therapy and taking oral contraceptives 




2.4.1 Non-Invasive and Invasive breast cancer 
 
Breast cancer can be divided into different types based on the cellular origin of 
cancer cells. A traditional pathological-driven classification of breast cancer divides the 
disease into three common types of carcinomas where the cancer spreads from epithelial 
cells of the breast tissue: ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) 
and invasive lobular carcinoma (ILC)49. DCIS is typically a non-invasive breast cancer; 
however, several studies have reported on the propensity of DCIS to become invasive (~ 
40%)50, 51. IDC spreads from the milk ducts and invades into the fat tissue of the breast and 
has the ability to metastasize through the bloodstream or lymphatic system. ILC is another 
breast cancer type that starts in the lobules of the breast52; ILC is characterized by the loss 
of “E-cadherin” protein which is normally expressed in the epithelial tissue of breast53. 
Based on the presence of hormone receptors, invasive breast cancers can also be sub-
divided into groups of those that are hormone receptor positive or negative. Hormone 
receptor positive tumours express the estrogen (ER), progesterone (PR) or human 
epidermal growth factor receptor 2 (HER2) receptors. In hormone receptor negative 
tumours, the growth of cancer cells is not dependent on systemic hormone levels and as 
such hormonal treatments (endocrine therapies) are not effective for this type of tumour 
which tends to be more aggressive and thus, grows faster than hormonal receptor positive 
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tumours52, 54. More detailed information regarding these receptors is provided in the 
following sections.  
Apart from the hormonal receptor status of cancer cells, other traditional pathology-based 
classifications include tumour size, lymph nodal involvement and histological grade, all of 
which should be considered to determine the most appropriate treatment55. It should be 
noted that these factors still have limitations in classifying breast cancer patients accurately 
because some tumours with similar pathological characteristics may respond differently to 
similar treatments55. 
 
2.4.2 Histological grade 
 
The histological grade of breast tumours provides important prognostic information 
in the management of the disease by aiding clinicians to make treatment decisions. Higher 
grade tumours tend to be more aggressive as opposed to lower grade tumours. One of the 
most validated scoring systems is the Nottingham Histological Score (NHS) also known as 
Elston-Ellis grading system. NHS classifies tumours into three different groups by 
considering three pathological factors of tubular formation, nuclear differentiation and 
mitotic counts which represents mitotic activity of the tumour cells.  The combination of 
these features (scored 1-3 for each factor) makes a final score representing the final grade 
of the tumour from Grade I with 3-5, Grade II with 6-7 and Grade III with 8-9 score, 
respectively56.  
 
2.4.3 Clinical and pathological staging 
 
Clinical staging is an estimation of a cancer spread, based on tumour biopsies taken 
from patients and a physical examination or tumour images. This approach is essential to 
choose initial treatment strategies especially before surgical interventions. Pathological or 
surgical stage of cancer is based on the reports of clinical staging. Additionally, 
pathological stage provides more precise information about cancer that has been obtained 






2.4.4 The TNM system 
 
The American Joint Committee on Cancer (AJCC) has proposed the TNM staging 
system as a standardized approach to classify cancer patients. TNM defines the prognosis 
and treatment recommendations of breast cancer patients by considering pathological and 
clinical staging of the tumour56.  
The TNM system classifies cancers into different stages based on the information about the 
primary tumour size “T”, the lymph node involvement “N” and metastasis spread “M”.  
The cancer could be categorized based on different features of the primary tumour into 
seven groups of Tx, T0, Tis and T1-T4; from unmeasurable tumour (Tx) to larger tumours 
that invaded the nearby tissues (T4). Lymph node involvement is another factor considered 
in TNM system.  N is categorized according to the size, location and number of involved 
lymph nodes into five different groups of Nx, N0-N3 and the higher number indicates more 
aggressive cancer that has spread to the nearby lymph nodes. M0 and M1 represent positive 
or negative the status of metastatic tumour, respectively. Detailed information regarding 




 BREAST CANCER SUBTYPES 
 
Clinical management of breast cancer greatly depends on the clinicopathological factors of 
tumours. These factors have strong association with patients’ prognosis and survival 
outcome. In routine clinical practice, three biomarkers of hormone receptor (Hr) status, 
including ER, PR receptors in addition to HER2 and a marker of proliferation “Ki67” are 
assessed to form the base of the adjuvant therapy given to patients. Assessment of Hr in 
addition to HER2 provides significant prognostic and predictive information regarding the 
response to hormonal therapy and HER2 targeted treatment, respectively. These 
information have improved our understanding about molecular features and heterogeneity 
of breast cancer.  The ER, PR, HER2 and Ki67 biomarkers are explained in further detail in 





2.5.1 Estrogen receptor alpha  
 
ERα is a transcription factor expressed by the ESR1 gene in several organ and 
overexpression of ERα is commonly observed in patients with early stage breast cancer58. 
The expression of ERα is a strong prognostic and predictive biomarker in breast cancer 
patients and is routinely assessed in clinics by immunohistochemistry (IHC) staining in 
order to give treatment recommendations to breast cancer patients58, 59.  
Patients with ERα positive (ER+) tumours account for more than half of breast cancer 
incidences and these patients have better outcome relative to ERα negative (ER-) patients 
due to better response to anti-hormonal therapies such as Tamoxifen60. Recent 
recommendation guidelines state that tumours should be considered ER+ if more than 1% 
of tumour cells show positive nuclear staining by IHC tests61. However, some retrospective 
studies have shown that different threshold would be required for the ER status of the 
tumours since patients with 1-9% ER positivity have shown worse outcome relative to 
patients with tumours that are ≥ 10% ER+ in which the former group do not benefit from 
endocrine treatments62, 63. 
 
2.5.2 Progesterone receptor 
 
PR status is used as a prognostic biomarker for ERα function in breast cancer patients64. PR 
is an ERα associated protein that controls ERα chromatin binding and transcriptional 
activity64. Additionally, PR has been shown to be a prognostic and predictor biomarker for 
early-stage breast cancer patients who have received adjuvant treatment in which, patients 
with ER+/PR+ tumours benefit more from hormonal therapy compared to ER+/PR-65. 
Furthermore, the importance of PR in relation to response to endocrine treatment has been 
studied66. Nevertheless, very little known about PR relative to ER and no targeted therapies 
have been proposed for the patients who might benefit from combined PR targeted 
treatment with standard ER targeted therapies. 
 
2.5.3 Human epidermal receptor 2 
 
HER2 also known as HER2/neu or ERBB2 is a transmembrane receptor tyrosine 
kinase belonged to epidermal growth factor receptor family (EGFR). ERBB2 plays an 
important role in several human malignancies. Overexpression of HER2 protein and 
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amplification of ERBB2 gene have been observed in 15-30% of invasive breast tumours. 
The majority of patients with ERBB2 gene overexpression had worse overall survival (OS) 
and poor prognosis until the ERBB2 targeted therapy with Trastuzumab was approved to 
treat these patients67. 
Trastuzumab is a monoclonal antibody that targets ERBB2 gene and is routinely used as a 
targeted therapy for patients whose tumours show overexpression of HER2 protein or 
amplification of ERBB2 gene. There are two routine clinical tests available to stratify 
patients based on their HER2 receptor status: either by assessing the overexpression of 
HER2 protein using IHC or by fluorescence in-situ hybridization (FISH) which is used to 
determine ERBB2 gene amplification68.  
 
2.5.4 Ki67 – a marker of proliferation 
 
Uncontrolled proliferation is a distinct feature of different malignancies. There are 
several methods to assess proliferation including mitosis counting, flow cytometric or 
assessment of Ki67 antigen69. Ki67 is present in all active cell cycle phases (G1-S-G2 and 
M phases) while it is absent in the G0 phase of the cell cycle70. Ki67 staining is routinely 
used in a clinical setting to measure proliferation. Furthermore, several clinical studies have 
demonstrated Ki67 as an independent prognostic factor for OS in breast cancer patients71, 72. 
Ki67 protein prevents chromosomes from breaking down into a single bulk chromatin after 
the prophase phase of mitosis by interacting with the mitotic spindle leading to a normal 
genome replication73. Ki67 status carries a very important therapeutic implication in breast 
cancer patients; it can be used to stratify low-risk patients with luminal A tumours from 
more proliferative luminal B tumours since the latter respond better to adjuvant 
chemotherapy74.  
Although the clinical significance of Ki67 has been proven in several studies for breast 
cancer patients71, 72, 74, there is still a lack of systematic methods to assess Ki67 in routine 
clinical practice. The international Ki67 in Breast Cancer Working Group proposed detailed 
guidelines to address this problem75. In this guideline, all issues regarding handling of 
tumour samples, fixation methods and recommended antibodies have been addressed75. 
According to the guideline, both core-biopsies and whole tumour sections are acceptable 
for the Ki67 scoring. In order to perform a prognostic assessment, the invasive area of a 
tumour should be considered to score Ki67. Additionally, the scoring result should be 
presented as a percentage relative to the total number of invasive cells in the scoring area75.  
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The cut-off for Ki67 has changed in recent years; however, in the 14th Saint Galen 
Consensus Meeting, the “≥ 20%” cut-off was defined as “high Ki67” status to differentiate 





 MOLECULAR SUBTYPES 
 
As noted in previous sections, ER, PR, and HER2 receptor status along with Ki67 
expression level are used as IHC surrogates for the classification of breast cancer tumours 
into 4 distinct subtypes including: luminal subtypes (A/B), ERBB2+/HER2-positive and 
Triple negative subtypes. All of these subtypes display different prognosis, response to 
treatment and distinct pattern of metastatic spread and survival time77–82. 
Luminal subtypes (ER+, PR+, HER2-): luminal tumours are the most common subtypes of 
breast cancer. These tumours show similar gene expression pattern to the genes in inner 
cells (luminal epithelial cells) of mammary ducts of a normal breast, including cytokeratin 
8/18, ER and genes associated with ER activation pathways. luminal tumours can be 
divided into two subtypes. 
 
Luminal A (ER+, PR+, HER2-/low Ki67): 30-70 percent of breast cancers are luminal A. 
According to the St. Gallen International Expert Consensus 2013, luminal A tumours are 
low proliferation tumours as measured by Ki67 with high expression of PR, moderate or 
high expression of ER, no expression of HER2 receptor and low pathological grade (1 or 
2). They tend to have the best prognosis relative to other breast cancer subtypes with low 
recurrence incidences and high survival rates77, 81. luminal A tumours are highly responsive 
to endocrine treatment and less responsive to (neo) adjuvant chemotherapy77.  
 
Luminal B (ER+, PR+, HER2-/high Ki67): 10-20 percent of breast cancers are of luminal B 
subtype. These tumours are highly proliferative and show lower expression of PR related 
genes relative to luminal A tumours. luminal B tumours are ER+, PR+ and tend to have 
poor prognosis with higher tumour grade, larger tumour size and they often have lymph 
node metastasis54, 83. luminal B tumours positively respond to endocrine treatment and are 
relatively more sensitive to (neo) adjuvant chemotherapy than luminal A tumours77. 
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Figure 6. Histological and molecular subtypes of breast cancer. 
(Adapted from McMaster Pathophysiology review - www.pathophys.org, Eric Wong, Jenna Rebelo 
and Sultan Chaudry.) 
 
HER2-positive (ER-, PR-, HER2+): 5-15 percent of breast cancers are HER2-positive 
subtype tumours. These tumours are characterized by amplified ERBB2 or high HER2-
protein expression and are highly proliferative; they show low or no expression of ER/PR 
related genes. These tumours often have higher pathological grade and high rate of liver 
metastases. HER2-enriched tumours response to (neo) adjuvant Trastuzumab treatment in 
combination with chemotherapy. They are also responsive to adjuvant anthracyclines and 
taxanes78–80. 
 
Triple-negative (ER-, PR-, HER2-): Around 15-20 percent of breast cancer tumours are 
triple negative.  These tumours are commonly diagnosed in younger age women with 
African ancestry. They have the worst prognosis compared to other breast cancer subtypes 
with high metastasis rates84–86. These tumours do not show any expression of ER, PR and 
HER2.  
It has been demonstrated that 45% of patients with triple-negative tumours have a 
pathological complete response (pCR) to anthracycline or anthracycline and taxane-based 
(neo) adjuvant chemotherapy77 and 17% of them have shown a pCR to neoadjuvant 





 INTRINSIC SUBTYPES 
 
Breast cancer is a heterogenous disease composed of multiple subtypes with unique 
morphological features and clinical outcomes. Technological advancement in the field of 
cancer discovery with high throughput platforms has helped us to understand the 
heterogeneity of the disease at a molecular level. Almost two decades ago, Perou et al. has 
demonstrated distinct gene expression patterns of breast cancer subtypes using the 
microarray-based classification technique. They proposed an initial list of 8102 genes 
involved in breast cancer progression87, which was subsequently reduced to an intrinsic 
subset of 496 genes using a hierarchical clustering method. The expression pattern of 
intrinsic genes divided tumour samples into two main groups of ER+ and ER- cancers87. In 
2001, Sørlie et al. described a distinctive “molecular portrait” of breast cancer using 456 
cDNAs in which tumours were classified as five intrinsic subtypes of luminal A, luminal B, 
HER2-enriched, basal-like and normal-like tumours. Patients with different subtypes have 
different clinical outcomes88. The intrinsic subtypes exhibit distinguishable gene expression 
profiles among tumour samples (Figure 7).  
Figure 7. Intrinsic subtypes of breast cancer: A) Five subtypes were identified in 85 samples based on their 
gene expression pattern. Luminal A/B/C in dark-blue, yellow and light blue, respectively; normal-like in 
green, basal-like in red and ERBB2+ in pink. B) C. ERBB2 amplicon cluster, D. Novel unknown cluster, E. 
Basal epithelial cell-enriched cluster, F. Normal-like cluster and G. Luminal epithelial gene cluster enriched 
with ER. Green represents down-regulation, Red represents up-regulation (Taken from Sorlie et al 2001). 
 
30 
In a furtherance of exploring the intrinsic subtypes of breast cancer, Hu et al. tried to 
refine the list of genes included in the intrinsic subtypes. They proposed a new list of 306 
genes which were associated with significant differences regarding OS and relapse free 
survival89. Following up on the Hu discovery, Parker et al., used a supervised clustering 
method known as Prediction Analysis of Microarray (PAM) and decreased the number of 
genes to 50. This new classification method is known as PAM50.  
PAM50 is comprised of Hr genes, proliferation genes and the genes that show basal and 
myoepithelial features (Figure 8)90.  The significant prognostic and predictive value of the 
PAM50 signature has been demonstrated in several retrospective clinical studies91–94. 
Differences between PAM50 subtypes are presented in table 1.  
 
 
Figure 8. 50 genes included in PAM50 signature; the relative expression of 
genes included in each subtype are shown in red/green colors whereas black 
color indicates that genes were not chosen for the given subtype (Taken from 




Table 1. Clinicopathological characteristics of PAM50 subtypes in breast cancer 
 Luminal A Luminal B HER2-Enriched Basal-like 
Variables 30 - 70 % 10 - 20 % 5 - 15 % 15 - 20 % 
     
ER* 
Positive Positive Positive/Negative Negative 
     
PR* Positive/negative Positive/negative 
Negative Negative 
(High) (Low) 
     
HER2* Negative Positive/negative Positive Negative 
     
Ki67* Low High High High 
     
Tumor grade 1 or 2 / low High High High 
     
LN status Negative Positive Positive Positive 
     
Common mutations 
TP53 - FOXA1 - 
PIK3CA 
TP53 - PTEN - 
PIK3CA 
TP53- APOBEC - 
PIK3CA 
BRCA1 - TP53 






    
Endocrine therapy Endocrine therapy Anti-HER2 (Trastuzumab)  
     
Prognosis High survival rate Low survival rate Early recurrence Aggressive 
 Low recurrence   Metastatic Metastatic  
 Best prognosis  Poor prognosis Poor prognosis Worst prognosis 
     
Metastases sites 
Bone Bone Liver 
Lung 
Brain 









 PROGNOSTIC & PREDICTIVE FACTORS IN EARLY BREAST CANCER 
 
After diagnosis of an invasive breast cancer, the first challenge is to identify patients 
who may benefit from adjuvant or neo-adjuvant treatments followed by choosing a proper 
therapy or combined treatment type for the diagnosed patients. Prognostic and predictive 
biomarkers address these challenges and help physicians to accurately make therapeutic 
recommendations. Prognostic factors are features representing a disease or a patient’s 
characteristics at the time of surgery which can be correlated to natural history of the 
disease. These factors are mostly associated with OS or DFS. Predictive factors are 
indicative measurements exhibiting the likelihood that a patient will respond to a given 
treatment. In the following sections several prognostic and predictive factors involved in 
early and advanced breast cancer will be discussed in detail. 
 
2.8.1 Axillary lymph node status 
 
In patients diagnosed with an early stage breast cancer, involvement of axillary lymph 
nodes (LN) and increased number of engaged LN are highly associated with poorer 
outcome95, 96. In a previous report, LN+ patients with > 3 lymph nodes involved show lower 
5-year median DFS relative to LN+ with ≤ 3 lymph nodes involved and therefore (5.4 years 
vs. 11.1 years ,  P < 0.001)96 due to the high risk of distance metastases in LN+ patients 
with > 3 lymph nodes involved, adjuvant therapy should be given to these patients97. The 
strong prognostic value of LNs has consistently been shown in several studies98–101; 
however, some studies reported that LNs may not directly involved in the establishment 
distance metastases102, 103.  
 
2.8.2 Tumour size 
 
The size of a primary tumour is another independent prognostic factor correlated with 
worse survival outcome in breast cancer patients58, 104. A study conducted under the 
Surveillance, Epidemiology, and End Results (SEER) Program has shown that patients with 
tumours between 2 to 5 or > 5 cm have worse 5-year breast cancer relative survival 
compared to patients with smaller tumours < 2 cm, respectively (79.8% and 62.7% vs. 
91.3%) 105. A similar trend has been demonstrated in another study with 20 years follow up 
where patients with larger tumours show shorter recurrence free survival (RFS) (75.5% +/- 
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2.3% for  ≤ 2 cm vs. 63.2% +/- 3.1% for 2-5 cm ; P < 0.001, respectively)106. Additionally, 
in a recent population-based study, tumour size was reported as an independent prognostic 
factor for OS, breast cancer specific survival (BCSS), locoregional recurrence and distance 
metastasis(≤ 2.0 vs. > 2.0cm, Hazard ratio (HR) = 2.3, 95% CI, 1.13 – 4.78)107. 
 
2.8.3 Tumour histological grade 
 
As previously mentioned, tumour grade is an important factor for the patients’ prognosis in 
breast cancer. The NHS is a widely used grading system due to its higher reproducibility 
compare to other methods108, 109. The NHS grading system has been described in section 
2.4.2. 
 
2.8.4 Lymphovascular invasion 
 
The lymphatic vessel and vascular invasion (LVI) have been demonstrated as an 
independent prognostic factor for BCSS (HR = 1.7 , P =  <0.0001)110 and DFS (Relative 
risk (RR) = 2.489, 95% CI, 1.147-5.398)111 in breast cancer patients. However, in a 
population-based study, LVI lost its strength as an independent prognostic factor to identify 
high-risk patients (P = 0.65)112.  LVI is mainly considered as an additional guide to make 
therapy decisions for LN- patients who have borderline tumour sizes.  In a retrospective 
study with 31 months follow-up, patients whose tumours exhibiting LVI have shown 
shorter progression free survival (PFS) and OS after neo-adjuvant chemotherapy(PFS:HR = 
3.76 95% CI, 2.07-6.83, and OS:HR = 5.70 95% CI, 2.08-15.64, respectively)113.  
 
2.8.5 Age  
 
Age at the time of diagnosis is considered as an important prognostic factor to identify 
patients with higher risk of recurrence (Rr). In several studies, the age of older patients has 
been shown to have a minor influence on their prognosis (Rr = 2.25, 95% CI, 1.66, 3.06)114 
(≥ 75 years, Relative survival rate (RSR) = 0.59, 95% CI, 0.57 - 0.61 vs. ≤ 34 years, RSR = 
0.62, 95% CI, 0.58 – 0.66)115; additionally, younger women have shown to have worse 5-
year cancer specific survival (CSS) compared to matched older patients  (> 80 years vs. ≤ 





The ethnicity of patients has been investigated in relation to prognosis among different 
populations. Investigators suggested that several other factors may have been involved in 
the survival outcomes of patients with different ethnical background. Influential factors 
including limited access to healthcare and treatment facilities, tumour types, obesity or low 
rate of mammography screening screen were included in the report117. However, African-
American women with early stage breast cancer who have gone under conservative surgery 
followed by radiation therapy have shown higher regional or distance recurrence rates 
along with lower RFS and OS (P = 0.01 and P = 0.0002, respectively)118. In another study, 
south-Asian women with Indian heritage have been compared to non-Asian (British-native) 
women where the former group showed higher 10-year RSR after the diagnosis 
independent from age, socioeconomic status and disease stage (South Asian:RSR = 72.6%, 
95% CI: 69.0, 75.9% vs. non-Asian:RSR = 65.2% , 95% CI:64.5, 65.8%)119.  
 
2.8.7 Proliferation Marker 
 
The prognostic capacity of Ki67, a proliferation marker in breast cancer has been 
tested in a large meta-analysis with more than 12,000 patients with early stage breast cancer 
in which, patients with high Ki67 had higher risk of relapse and worse DFS (HR = 1.93, 
95% CI, 1.74 – 2.14, P = 0.001) and OS (HR = 1.95, 95% CI, 1.70 – 2.24; P = 0.001)71. 
The predictive capacity of Ki67 has also been reported as a surrogate marker for clinical 
response to hormonal treatment in breast cancer patients120–122. In the Breast International 
Group Trial (BIG) 1-98, Ki67 was used as a predictive marker in the adjuvant setting where 
treatment with Tamoxifen was compared with Letrozole. In this study, patients with higher 
proliferative tumours measured by Ki67 responded better to Letrozole over Tamoxifen and 
had longer DFS (HR[Letrozole: Tamoxifen] = 0.53; 95% CI, 0.39 to 0.72)122. Other studies 
have examined the predictive role of Ki67 in the neo-adjuvant setting120, 121. Both studies 
have shown a similar trend in which, patients with high Ki67 expression responded better to 
the treatments (Clinical response, P = 0.02 and Pathological response, P = 0.045)121(P < 





2.8.8 ER/PR and HER2 status 
 
The assessment of the prognostic capacity of ER and PR is difficult due to the 
administration of adjuvant endocrine therapy; however, in a randomized clinical trial where 
none of the participants received systemic adjuvant treatment, ER+ patients have shown 
longer 5-year DFS relative to ER- patients (P = 0.005)123. Nevertheless, in a longer follow 
up study ER+ patients only exhibited better prognosis in the first 3 years of the follow-up 
while ER lost its prognostic significance after 3 years124. Despite limited prognostic 
strength of ER and PR, they provide significant predictive value. 
As noted in section 2.5.3, overexpression and amplification of ERBB2 were correlated with 
poorer prognosis before the routine administration of anti-HER2 treatments. Nevertheless, 
HER2+ patients treated with Trastuzumab have shown better prognosis when compared 
with HER2- patients, owing the therapeutic advantage of anti-HER2 regimen (OS:HR = 
0.67, 95% CI: 0.48 - 0.92)125. In addition to prognostic capacity of HER2, several studies 




 PROGNOSTIC & PREDICTIVE FACTORS IN METASTATIC BREAST 
CANCER 
 
Most of prognostic and predictive factors of early stage breast cancer are well known 
however the knowledge is not well defined in metastatic breast cancer tumours (MBC). 
Regardless of the improvement in efficacy of treatments for early breast cancer patients, 
around one third of these patients will eventually develop metastasis126. The survival time 
for MBC patients varies between 24 - 36 months after the first relapse127. Therefore, 
identifying prognostic and predictive factors in MBC are essential for better treatment 
recommendation. In the following sections some of these factors will be discussed.  
 
2.9.1 Hormone receptor and HER2 status  
 
Different breast cancer subtypes have been shown to be correlated to different 
outcomes in MBC patients each of which has distinct pattern of metastatic root128. 
Kennecke et al. have demonstrated that MBC patients with luminal subtype tumours have 
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longer survival time relative to MBC patients with HER2-enriched or basal-like tumours128. 
Additionally, patients with luminal A/B subtypes showed lower rate of brain metastasis 
relative HER2-enriched and basal-like subtype tumours128. Several studies reported a 
relatively better outcome in MBC patients with hormonal positive (Hr+) /HER2+ primary 
tumours while triple negative tumours have the shortest survival rate among the patients129. 
In a retrospective study conducted before administration of anti-HER2 drugs, MBC patients 
with HER2+ subtype tumours show worse survival outcome compared to Hr+/HER2- 
tumours regardless of Hr status128. However, MBC patients with HER2+ tumours who were 
treated with Trastuzumab have shown a better prognosis compared to HER2- MBC (HR = 
0.56; 95% CI, 0.45 - 0.69; P < 0.0001)130. Some recent reports the changes in the subtype 
of primary tumours have been compared to MBC in some patients131–133 in which the 
metastatic tumours have lost/gained HER2 or Hr receptor status in MBC patients134, 135. In 
latter study, patients with ER+ MBC have better prognosis compared to ER- MBC, 
regardless of ER status of their primary tumours135; however, MBC patients with Hr-
/HER2- tumours in relapse sites have shown poorer prognosis (HR = 1.48; 95% CI, 1.08 - 
2.05)135. 
 
2.9.2 Initial metastatic sites 
 
Several studies have been demonstrated the significance of the site of metastasis in 
prognosis of MBC patients. OS was shown to be better among MBC patients whose 
tumours have relapsed to the bone compared to the visceral or brain metastases136–139; 
similarly, metastases to the liver or distant lymph nodes reduced the survival rate in MBC 
patients136, 140. 
 
2.9.3 Age at the time of relapse 
 
The age of MBC patients at the time of relapse has been poorly explored. Although in a few 
reports, the higher age and shorter OS and BCSS have shown to be directly correlated; the 
poorer outcome in elderly women could be related to the higher treatment related mortality 
rate in these patients 139, 141, 142. Sabiani et al. have reported that younger women often have 
more aggressive tumours and poorer DFS (≥35years, Triple negative = 22.2% and HER2 
tumours = 22.1%, respectively, P < 0.01, DFS:HR = 1.995)143. Also, these patients show 
higher risk of local and/or distance metastases as well as higher incidences of lymph node 
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metastases([>36 vs. > 35 years], 21.5%,15.4% ; [>36 vs 40 years], 21.8%,12.6%, P < 0.01) 
143.  
 
2.9.4 Prior Adjuvant treatment 
 
Despite early detection of the breast cancer and administration of adjuvant 
treatments, the impact of the treatments on OS in MBC patients is very small and 
controversial. Some population-based studies reported longer survival time in Hr+ MBC 
patients who have received hormonal treatments in the primary setting 144, 145 while others 
stated small, no significant difference or decrease patients survival146–148. This could be due 
to the appearance of more aggressive and treatment-resistant tumour cells in MBC patients 
who were given adjuvant treatment at the early stage of the disease148.  
 
2.9.5 Metastasis-free interval 
 
Metastasis-free interval (MFI), defined as the time of diagnosis of a primary breast cancer 
to the first distance metastasis has shown to be an independent prognostic factor in MBC 
patients149. A report shows that a survival outcome in patients with MFI < 2 years was 
significantly lower than the ones with MFI ≥ 2 years in a univariate analysis150. Another 
study, reported MFI > 10 years is associated with longer survival time in MBC patients and 
lower risk of metastatic BCSS mortality (HR = 0.77, 95% CI, 0.65–0.90; P = 0.191 and 
< 0.001, respectively)151. 
 
2.9.6 PI3K pathway – alterations in PTEN and PIK3CA genes 
 
PTEN and PIK3CA oncogenes play key roles in activation of the PI3K pathways and are 
involved in resistance to Trastuzumab152. Mutations in PIK3CA and low expression of 
PTEN have been reported to have direct association with poor prognosis in MBC patients 
who have gone under Trastuzumab therapy. Also, patients who have alterations in both 
PTEN and PIK3CA have higher risk of disease progression compared to patients with only 
PTEN alteration153. Similar results have been shown in another study in which HER2+ 
MBC patients with mutated PIK3CA had poorer response to Trastuzumab subsequently had 
shorter survival time(P = 0.047 and P = 0.015, respectively)152. 
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2.9.7 BRCA1/BRCA2 genes 
 
In a phase I trial of advanced breast cancer tumours, MBC patients with germline 
mutations in BRCA1/BRCA2 reported to have better response to Talazoparib154; 
additionally, in a randomized study HER2- MBC patients with germline BRCA mutations 
responded to the treatment with Olaparib155. Moreover, BRCA2 mutation carriers with 
sporadic breast cancer have reported to have higher risk of distant recurrence in univariate 
analysis(HR = 1.81; 95% CI, 1.15 to 2.86; P = 0.01)156.  
 
2.9.8 ESR1, ERBB2 genes 
 
ESR1 mutations in the ligand binding domain of ERα receptor are known to be involved in 
resistance to aromatase inhibitors (AI) by forming a ligand-independent interaction with ER 
157, 158. The majority of MBC patients with ESR1 mutations exhibit poorer survival outcome 
and shorter PFS in metastatic tumours after given AI therapies159, 160.  
Therefore, ESR1 mutation could be used as a predictive biomarker to select patients who 
may benefit from combination or selective endocrine therapies. In a prospective-
retrospective phase III randomized study, ESR1 mutated patients have shown better PFS 
after receiving Fulvestrant combined with Exemestane compared to the patients who did 
not carry this mutation.161 In another study patients with ESR1 mutated gene treated by 
Exemestane in combination with Placebo or Everolimus, had shorter OS in comparison to 
wild-type ESR1 gene162. 
MBC Patients who acquired mutations in ERBB2 in their relapsed tumours may not 
response to Lapatinib163. However, MBC patients with mutated ERBB2 show response to 
Neratinib alone or in combination with Capecitabine suggesting that these patients are good 
candidates for Neratinib or Neratinib combined treatment164.  
 
2.9.9 Intrinsic subtypes of MBC 
 
Several studies have reported changes in clinicopathological characteristics of early breast 
cancer to metastatic lesions during cancer progression135, 165, 166. The intrinsic subtypes of 
MBC tumours have shown to provide prognostic information regarding post-relapse 
survival for MBC patients where HER2-enriched and basal-like subtype tumours had worst 




2.10.1 Neo-Adjuvant therapies 
 
Neo-adjuvant treatments are mostly offered as chemotherapy (NAC) to early stage 
breast cancer patients to downstage their tumour. Large clinical trials reported no benefits 
from NAC regarding DFS (RR = 0.95; 95% CI = 0.88 - 1.10; P = 0.50)167, OS (HZ = 1.16; 
P = 0.38), PFS (HZ = 1.15; P = 0.27) and loco-regional recurrence (LRR) (HZ = 1.13; P = 
0.61)168 between pre or post-surgical treatments. Additionally, some concerns have been 
reported regarding the risks of neo-adjuvant treatments. However, neo-adjuvant therapies 
increase the opportunity for breast conservation treatment by lowering the tumour stage169. 
Although NAC reduces need of axilla lymph node dissection or mastectomy170 it 
significantly reduces the chance for fertility preservation in the young patients171; 
additionally, an increased rate of loco-regional recurrences have been reported in patients 
who have undergone neo-adjuvant treatment prior to surgery172. 
 
2.10.2 Surgery and radiotherapy 
 
Surgical removal of the tumour is an initial treatment for primary invasive breast cancer 
patients. Surgical techniques vary depending on the size and location of the tumour and 
include mastectomy or breast conserving surgery followed by radiotherapy. In a 
collaborative study conducted by Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) radiotherapy reduced loco regional recurrences by 10-years and breast cancer 
death after breast conserving surgery by 15-years173. In another report from EBCTCG 
group, the10-year risk of any first recurrences (Absolute reduction = 15,7%, 95% CI, 13.7–
17.7, P < 0.00001) and 15-year risk of breast cancer death (Absolute reduction = 3.8%, 
1.6–6.0, P = 0.00005) have been decreased in patients who have received radiotherapy after 
mastectomy174. 
 
2.10.3 Adjuvant systemic treatment 
 
Adjuvant systemic treatment is an effective therapy given to patients with primary invasive 
breast cancer to reduce risk of loco-regional or distance recurrences and include 






Several studies have shown that adjuvant chemotherapy reduces Rr in early breast 
cancer patients175–177. Adjuvant! Online is a web-based tool that is commonly used in 
clinics in order to assess the benefits of adjuvant treatments in breast cancer patients. Based 
on this tool adjuvant chemotherapy could be divided into three different regimens. These 
adjuvant regimens are generally comprised of two active cytotoxic agents including 
anthracyclines and taxanes. In the first combination adjuvant chemotherapy initiated by 
Bonadonna et al. in 1973, Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) 
were compared with the control population in a randomized study with LN+ patients who 
have undergone radical mastectomy. Patients who were given the combined treatment 
showed significantly improved DFS and OS178. Another study conducted by Mansour et al. 
reported a reduction in the Rr in LN- patients175.  
In a meta-analysis reported by EBCTCG, patients who have received CMF showed reduced 
Rr for 10-years and in overall mortality risk176. Combination of Cyclophosphamide with 
anthracyclines (AC) such as Doxorubicin has been tested in several trials179–181. In the 
National Surgical Adjuvant Breast and Bowel Project clinical trial (NSABP) B-15 trial, 
DFS and OS were similar between LN+ patients who have given AC compared to the 
patients who have received CMF180. Similar results were observed in LN- patients181. 
Several randomized trials tested the efficacy of combination therapy of Cyclophosphamide 
with Epirubicin and 5-Flourouracil (FAC) in ER+/LN+ patients182. Similar combination 
was tested in MBC patients in a tailored dose study183. An increase in DFS time by 9-years 
has been reported in ER+/LN+ patients while OS rate was the same182.  
In a metastatic cohort, increased DFS (HR = 0.63; P = 0.02) and OS (HR =  0.45; P = 0.005) 
was reported in the higher dose compared to lower dose treatment183. Efficacy of FAC was 
compared with Docetaxel, Doxorubicin, and Cyclophosphamide (DAC) in several 
randomized trials184, 185. Both trials showed the improvement in DFS (HR = 0.80; 
P = 0.0043) and OS (HR = 0.74; P = 0.002) in the first, and DFS (HR = 0.68; P = 0.01) in 
the second trial, respectively in favor of DAC treatment arm over FAC. In general, adjuvant 
chemotherapy reduces Rr in the early stage and MBC patients irrespective of age, axillary 
lymph node, Hr status or tumour grade and prior Tamoxifen treatment176.  
 
2.10.3.2 Endocrine therapy 
 
As mentioned in the previous sections, only Hr+ patients respond to endocrine treatments. 
The benefit of 5-years Tamoxifen administration in Hr+ patients has been previously 
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reported186. Early stage breast cancer patients who have received 5 years adjuvant 
Tamoxifen treatment show lower Rr up to 15 years compared to patients who have only 
received the treatment for 2 years186. Furthermore, results from a randomized ATLAS trial 
show that ER+ patients who have received Tamoxifen for 10 years show a further decrease 
in Rr and mortality rate in comparison to those were given Tamoxifen for 5 years60. AI was 
given to postmenopausal patients as an additional treatment to endocrine therapy. Results 
from Austrian Breast and Colorectal Cancer Study Group (ABCSG)-16 showed 5 years AI 
treatment after adjuvant Tamoxifen therapy did not increase DFS compared to patients who 
received this combination therapy (HR = 1.007; P = 0.947)187.  
 
2.10.3.3 Anti-HER2 therapy 
 
Adjuvant anti-HER2 treatment with Trastuzumab improves survival in patients 
overexpressing HER2125 in combination with anthracycline-based regimens188. One-year 
Trastuzumab treatment is a standard duration given to HER2+ patients however, this 
combination therapy shows higher cardiac toxicity among treated patients.  Therefore, some 
studies explored shorter duration of the treatment with 1-year standard Trastuzumab 
treatment189, 190, the results of a meta-analysis study have shown that patients who have 
treated for 1-year show improved OS (HR = 1.28, p=0.04), and DFS (HR = 1.24, p=0.005) 
compared to shorter durations190. However, investigators of a large phase III randomized 
treatment “Persephone” recommended at the latest annual American Society of Clinical 
Oncology (ASCO)-2018 meeting to reduce the Trastuzumab treatment for early breast 
cancer patients to 6 months since majority of these patients show cardiac or other toxicities 
between 7-12 months after the treatment. The results from Persephone trial show 
comparable benefits for the patients who have been treated for a shorter duration compared 
to one-year standard regimen191. Pertuzumab is another FDA (U.S. Food and Drug 
Administration) approved anti-HER2 monoclonal antibody drug to treat HER+ breast 
cancer patients. Pertuzumab could be admitted in both neo-adjuvant and adjuvant 
settings192, 193. Additionally, patients with metastatic HER2+ tumours in the CLEOPATRA 
trial showed an increase in OS (median 56.5 months) under combination treatment of 
Trastuzumab and Docetaxel in addition to Pertuzumab, compared with Trastuzumab and 






3 MICROARRAY DATA ANALYSIS 
 
Microarrays were introduced for the first time in mid 1990s195. Since then this 
technology became one of the most extensively used methods in cancer research. 
Microarrays are employed to study in a large-scale the expression of genes. A microarray 
slide has numerous spots in defined locations on the slide that contain many single-strand 
DNA or RNA sequence fragments so-called “probes” which are complementary to a gene 
of interest.  The probes labelled with fluorescent dyes are attached in different locations on 
a solid substrate of the array and bind to their complementary DNAs (cDNA) on the slide 
by a process known as “hybridization”. Subsequently, a detector measures the intensity of 
fluorescent light emitted from the bound matched probes that signifies the expression of a 
gene of interest. Microarrays can be divided into two main groups of Single- and Two-





Single-channel microarrays can only be used to detect labelled probes rather than 
direct comparison between samples since only one sample is hybridized per each probe. 
Therefore, separate hybridizations are required to compare the conditions for the same 
gene. It should be noted that the signal intensity in the single-channel microarray is an 
absolute value, representing expression level of a predetermined probe/gene. However, it 
could be seen as a relative expression value when the predetermined probe/gene is 
compared to another condition or a probe. Affymetrix GeneChips are a one-channel 
microarray platform which is commonly used in cancer research. In total around 900,000 
oligonucleotides are directly placed on the glass surface of the array. A combination of 
different oligonucleotide probes represents different genes.  
The Affymetrix microarray probes are 25-mer long and consist of two different probes: 
Perfect match (PM) probes contain the complimentary sequence of a gene of interest thus 
representing the expression level of that particular gene. Mismatched probes (MM) have a 
single base mismatched sequence in the middle of the probes that are used to distinguish 






Dual- or two-channel microarrays are comprised of two cDNA samples that are labelled 
individually with two different fluorescent dyes “Cy3” and “Cy5” with different 
wavelength, respectively. Two labelled samples will be hybridized together allowing 
investigators to have a quantitative and direct comparison between two probe samples on 
the same array. The signal intensity in the dual-channel method represents a relative gene 
expression within and between samples that are located on the array. Therefore, dual-
channel method is very efficient in comparative experiments. A schematic view of a two-







Figure 9. Different steps of two-channel microarray experiment. Two 
samples are labelled with different florescent dyes and hybridized on a 
same probe. Subsequently, the signal intensities of the samples are 





The output from the microarray is often noisy and highly dimensional. Therefore, 
“trimming” the microarray data is essential for further analysis in order to extract relevant 
biological information from the experiment. In the preprocessing step, systematic errors 
caused by labelling, hybridization and scanning are removed, thus making the data 
comparable across multiple arrays. Several preprocessing methods have been proposed and 
yet there is no consensus on the choice of ideal preprocessing strategy199–201. Despite 
availability of different preprocessing methods based on microarray platforms, all of them 
consist of three main steps: Background correction, normalization and summarization.  
 
3.3.1 Background correction 
 
Background noise in microarray data impacts the signal intensity detected by the 
scanner. Background noise can be generated by non-hybridized probes a non-specific 
hybridization. As a result, background correction is needed to reduce the bias and increase 
the measurement accuracy of the signals. Various methods are available to estimate and 
adjust the background noise in microarray experiments. One of the most common 
algorithms for background correction in one-channel arrays is Affymetrix MAS 5.0202. In 
this algorithm, each chip breaks to a defined equal sized area “k”. Then, a weighted average 
of lowest 2% of each region is chosen to calculate the local background of that explicit area 
Bk on the chip. Furthermore, MM probes are used as a complementary measurement of the 
background noise for PM probes in the k areas Nk. Then, the background noise of each 
specific probe in each particular geometrical location “(x , y)” is calculated by summing up 
of all Bk and Nk, respectively “Ba“, “Na“. Moreover, for each k area, the local background 
Ba is subtracted from the raw intensity in that particular (x , y) location of the probe; unless 
this leads to a value lower than the noise value Na, in that location. In that case, the probe 
intensity will be replaced by Na203. 
Another commonly used background correction method is Robust Multi-Array Average 
(RMA)204. RMA estimates the signal intensity across all arrays by exclusively using PM 
probes while ignoring MM probes which may reduce the precision of the measurement 
system for the RMA method205. Including or excluding the MM probes in the background 
correction step subsequently impacts the choice of normalization and summarization 
techniques in the downstream analysis of the microarray data206, 207.  
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Background correction of dual-channel microarray is usually achieved by subtracting 
values derived from the local background signals from the foreground ones. This approach 
greatly reduces the bias in the analysis. However, variance of lower signals can 
subsequently be magnified, causing new systematic artifacts. Therefore, there is a debate 
whether one should perform or ignore the background correction on the data derived from 




Several methods have been proposed to normalize microarray data and all of them attempt 
to remove systemic variations and balance the intensities of individual hybridizations in 
microarray experiments.  
In the following sections, some of common normalization methods for microarray data 
including a) Standardization, b) Housekeeping gene-based, c) Quantile normalization will 
be briefly discussed.  
 
3.3.2.1 Z-Score - Standardization 
 
In the Z-Score method, gene expression data is normalized using the logarithmic value of 
signal intensities “log(s)”; log(s) values are normalized in order to have mean “μ” or 
median value “M” of 0 and standard deviation “𝜎” = 1. The standardized values known as 
“Z-score” are calculated by subtracting the µ or M from log (s) and then, divided by 𝜎:	
 
Z = log (s) – (µ or M) / 𝜎	
 
3.3.2.2 Housekeeping gene-based 
 
In this method, the data are scaled based on the expression of the housekeeping genes (HK). 
The HK genes are the most common genes on a microarray and are assumed to have 
identical expression levels across all probes. However, this assumption has been proven to 
be false in several situations, especially across wider spectrum or several tissue types211, or 




3.3.2.3 Quantile normalization 
 
Quantile normalization aims to normalize probes’ intensities in order to have a same 
distribution across arrays in which the intensity of each array will be replaced by the mean 
intensity of its level200. A significant limitation of this method is related to a necessity of 
having the same number of values in each sample, thus making it inappropriate for 




In some microarray platforms such as Affymetrix, a gene of interest could be 
represented by multiple probes. Therefore, a summarization step is needed in order to 
generate a single expression value for each probe sets (~20 pairs of probes in Affymetrix) 
that are representative of a single gene. Different summarization algorithms are available 
such as Tukey Biweight used in MAS 5.0 and Medianpolish (as a part of RMA 
normalization pipeline)203, 204. In the Affymetrix platform, each individual chip has a 
definition file (CDF) that contains annotation information. CDFs are used to map probe 
signals to genes. However, several studies have shown that the accuracy of Affymetrix 
microarray experiments can be improved by updating the annotations of the probes 
provided in the CDFs. As a result, it can increase the reproducibility of microarray data 




 DIFFERENTIAL GENE EXPRESSION ANALYSIS 
 
Microarray technology has been available for almost three decades and is still widely used 
because of its lower costs compared to other methods. It is applicable in several aspects of 
cancer discovery such as identifying single-nucleotide polymorphisms (SNPs) or mutations 
and classifying tumour types. One common application of microarray technology is gene 
and transcript differential analysis in which the pattern of gene expressions between cancer 
patients and normal patients are compared; thereby, tumour suppressor or oncogenes 




 CLASSIFICATION METHODS 
 
Since microarray experiments generate a large amount of information, classification 
is essential to interpret the data in order to address relevant biological questions from the 
experiment. Classification methods are used to group samples/genes that share common 
features and distinguish them from other group of samples/genes e.g. a group of tumour 
samples vs normal samples. Additionally, classification can lead to the discovery of new 
groups or samples in the data e.g. identifying new subgroups of tumours within a specific 
cancer type. Unsupervised and supervised methods are two main approaches in microarray 
data analysis to classify samples. In the following sections these methods will briefly be 
discussed.  
  
3.5.1 Unsupervised classification 
 
In the unsupervised classification method, samples or genes are clustered with no previous 
knowledge regarding their class or group orders. Since no prior assumptions are involved in 
the clustering, unsupervised classification is impartial. Therefore, it represents a natural 
relationship between the samples e.g. genes that may have been involved in a similar 
pathway cluster together. Hierarchical clustering is one of the most common algorithms 
used in unsupervised classification.  
 
3.5.1.1 Hierarchical clustering 
 
Hierarchical clustering (HC) is used to group samples that are most similar into the same 
group known as cluster; each cluster has its distinct features that are shared within the 
cluster and are different from the other clusters.  In the HC algorithm, samples are 
considered as individual clusters initially. Then, the two adjacent clusters will be identified 
using a distance metric method. In the final step, the most two similar clusters will be 
joined into one cluster. These steps will be executed repeatedly until all samples are 
clustered based on their similarities.  
In order to perform HC, other factors such as measure of distance and linkage criteria 
should also be considered: 
1) Measures of distance: represent the similarities between the samples. Several distance 
methods have been developed; therefore, the appropriate distance method should be chosen 
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based on a research hypothesis215, 216. As an example, in a simple Euclidean distance 
method, the distance between two clusters is based on the length of a straight line drawn 
from one cluster to one another.  
2) Linkage criteria: is another factor in the HC algorithm that defines the position where 
distance should be calculated.  Most common linkage criteria are a) Single-linkage, is the 
point between the two most similar clusters which is used as the starting point of the 
measurement, b) Average-linkage, in which the central point of all clusters is selected as 
the starting point of the measurement and c) Complete-linkage, the distance between the 
two least similar members of a cluster will be selected as the base of the distance 
measurement216.  
A partitional method is another clustering method whereby each sample is considered as 
one subset such that samples are divided into non-overlapping partitions.   
Algorithms such as principle component analysis (PCA) have been introduced to reduce 
dimensionality of data217. In gene expression analysis, PCA initially considers genes as 
variables and then, generates a new variable that has linear correlation to the expression of 
those genes. Furthermore, variables/genes with the lowest variance compared to the new 
variable will be removed; subsequently, PCA reduces the complexity of the data, and 
emphasizing variation. It also reveals the interpretable pattern of gene expression in the 
dataset while keeping the most valuable information of the original data218. 
 
3.5.2 Supervised classification 
 
Supervised classification is based on a predictor with known features associated with 
an outcome which could be used to predict the class of a new/unknown sample. In 
microarray analysis, supervised classification is used to generate a classifier or a signature 
that can be validated in a blinded dataset; additionally, supervised classification can identify 
a gene list that is important for the classification. Different predictors can be used in 
supervised classification of microarray data e.g. ER/PR status of a tumour or 
histopathological tumour grade are common predictors used to predict an outcome in 
cancer patients. Several supervised classification methods have been developed including: 
support vector machines (SVM) and logistic regression or neural networks and their utility 
have been previously demonstrated219–222. The predictive power of a supervised classifier 
should be validated with a new independent dataset to prove its independency from the 
features that are available in a test dataset. 
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4 GENE EXPRESSION SIGNATURES 
 
In the context of breast cancer research and treatment, most of the prognostic and 
predictive factors noted here are known as clinicopathological characteristics of tumours 
and are used by clinicians to make therapeutic recommendations for breast cancer patients. 
It is appropriate to issue certain limitations regarding these factors. First and foremost, these 
factors are only partially independent from each other e.g. an ER- tumour is highly 
proliferative and tends to have high (II/III) tumour grade.  Second, whilst assessment 
methods of clinical biomarkers such as ER, PR and HER2 have been standardized in recent 
years, Ki67 measurement still has high interlaboratory variability with a questionable 
accuracy. Third, these factors are measured with different scales, e.g. ER/PR are measured 
as binary variables while Ki67 and patients’ age are continuous variables.  
Thereupon, a multivariate predictor or classifier which incorporates all these factors is 
required in order to achieve an accurate prediction for patients. In this regard, gene 
expression signatures/classifiers have been proposed and their clinical utilities have been 
studied93, 223–225. In the context of cancer classification, a gene signature can be defined as a 
gene or combination of genes whose expression profiles are explicitly associated with a 
particular diagnosis, prognosis or response to a specific treatment in cancer patients226. In 
general, gene expression signatures in breast cancer can be divided in two main groups of 
first-generation and second-generation signatures. The first-generation signatures are 
capable of predicting recurrences in cancer patients within 5 years after initial diagnosis 
whereas second-generation signatures can make an accurate prediction both in early and 
late (more than 10-year) recurrences.  












 BIVARIATE GENE EXPRESSION SIGNATURES 
4.1.1  70-Gene signature (MammaPrint) 
 
The 70-Gene signature is based on a DNA microarray platform and was initially 
developed on fresh frozen samples derived from 117 breast cancer LN- patients with < 5cm 
tumours. Despite not receiving systemic adjuvant treatment, half of the patients in the study 
were free from distance metastasis for at least 5 years. Therefore, investigators tried to 
generate a signature that could stratify the subgroup of patients with a low-risk of distance 
metastasis. Through the use of a supervised classification method, 70 out of 5000 initial 
genes were selected that showed the highest correlation with breast cancer prognosis.  
The 70-Gene signature classifies LN- patients with stage I/II tumours into low or high-
genomic Rr within 5-years after diagnosis. The signature has shown to have a significant 
prognostic capacity after being tested in a multivariate model, adjusting for all classical 
clinical prognostic factors (Odds ratio (OR) = 18.00, 95% CI, 3.3 - 94). The final 70 genes 
included in the signature are mostly involved in proliferation signaling, apoptosis 
resistance, invasion and metastasis well as angiogenesis227.  
The prognostic capacity of the 70-Gene signature has been validated in several 
retrospective studies. The predictive capacity of the signature has also been assessed where 
the 70-Gene signature predicts survival outcome for LN+ patients, in which patients in the 
low-genomic risk group show longer distant metastasis free survival times (DMFS) (98% at 
5-years, 91% at 10 years) relative to patients in the high-genomic group metastasis (80% at 
5-years, 76% at 10-years) respectively, when 1-3 nodes were involved228. Similar trends 
have been shown in patients with 4-9 lymph nodes involved229.  
Although, the 70-Gene signature has significant prognostic strength within 5-years after 
initial time of diagnosis, the prognostic capacity of this signature declined within a longer 
period of time230. Finally, the 70-Gene signature has also been validated in a prospective 
manner and it can be used to make treatment decisions in an adjuvant setting for early-stage 
breast cancer patients223, 231. 
In summary, 70-Gene signature has been validated in several retrospective, prospective and 
phase III randomized clinical trials; 70-Gene signature has been approved by FDA and is 





4.1.2 Genomic grade index (MapQuant DX) 
 
Histological grade of tumours (HG) is an important prognostic factor in breast 
cancer. Patients with high grade III tumours (HG3) show worse prognosis relative to low 
grade I tumours (HG1)232. However, the majority of tumours are classified as grade II 
tumours (HG2) with an intermediate Rr (30-60% of the cases) which makes it difficult to 
plan an effective treatment strategy for these patients. The Genomic Grade Index (GGI) 
signature was generated to address this problem by reclassifying HG2 tumours into GGI-1 
and GGI-3 in which the latter group has a higher tendency for relapse (HR = 3.61, 95% CI, 
2.25 to 5.78)224. 
The GGI signature is based on the Affymetrix microarray platform. In the original study 
investigators performed differential gene expression analysis on an initial training set of 65 
ER+ tumours, comparing HG3 with HG1 tumours. The final number of 97 genes that had 
the highest association with HG were identified and used to generate the GGI signature. 
Since most of these genes are related to cell cycle and proliferation signaling, GGI could be 
seen as a representative signature of proliferation wherein GGI-1 tumours represents low 
proliferation and GGI-3 represents high proliferation level, respectively.  
Furthermore, Sotiriou et al. have shown that GGI has the prognostic capacity to reclassify 
HG2 tumours into two groups of high and low Rr224. 
The GGI signature was shown to be able to predict response to combination neo-adjuvant 
chemotherapy with paclitaxel, fluorouracil, doxorubicin and cyclophosphamide, in which 
patients with GGI-3 were more sensitive to the treatment compared to GGI-1 patients233, 234  
In a follow up study, the GGI signature was modified to run on quantitative real-time 
polymerase chain reaction (qRT-PCR) assay on formalin fixed paraffin embedded samples 
(FFPE). The PCR-GGI is comprised of 4 genes (MYBL2, KPNA2, CDC2 and CDC10) 
associated with cell cycle progression and proliferation that were included in the GGI 
signature as well as 4 housekeeping genes (GUS, TBP, RPLPO and TFRC ). The PCR-GGI 
signature has been shown have reliable prognostic performance in comparison to GGI, 
particularly in ER+ patients235. 






 MULTIVARIATE GENE EXPRESSION SIGNATURES  
4.2.1 Recurrence score (Oncotype DX) 
 
The recurrence score (RS) is a RT-PCR based assay signature run on FFPE tissue samples 
in a central laboratory. This signature was initially tested on the FFPE samples derived 
from LN- patients who participated in the NSABP B-14 trial and have been treated only 
with Tamoxifen. Although chemotherapy has shown to reduce the RRs in early breast 
cancer patients236, 237, the benefit of additional chemotherapy may be minimal in some 
patients237. RS is developed to identify patients who benefit from chemotherapy in addition 
to hormonal therapy in an adjuvant setting238. The RS is comprised of 21 genes associated 
with tumour development and cancer progression in addition to 5 reference genes (Figure 
10).  The risk score of recurrence is in a range from 0-100 (RS < 18 = low, 18 ≤ RS < 31 = 
intermediate and RS ≥ 31 = high Rr, respectively). RS classifies patients with ER+/LN-, 
stage I or II tumours into three different risk groups of low, intermediate and high Rr within 
5-10 years after the initial time of diagnosis.  
 
Higher expression of the genes belonging to the ER group are associated with lower risk of 
recurrence while higher expression of the genes belonging to the Proliferation group, HER2 
group, invasion group and CD68 are considered to worsen patients’ prognosis238. Several 
retrospective studies have shown the prognostic and predictive capacity of RS239, 240.  
The RS has also been validated in a prospective clinical trial with more than 10,000 patients 
known as the Trial Assigning Individualized Options for Treatment (TAILORx). The early 
 
Fig 1. Oncotype Dx (Genomic Health, Redwood City, CA) recurrence score (RS): genes and algorithm. HER,
human epidermal growth factor; ER, estrogen receptor; PR, progesterone receptor.
Figure 10. Genes that are included in RS and their contribution in the risk score of 
recurrences. (Taken from Sparano et al. 2008.) 
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results of TAILORx study showed that patients with ER+/HER-/LN- tumours and low RS 
(0-10) have low risk of distance recurrences within 5 years241. Sparano et al. has recently 
reported follow-up results on TAILORx study, demonstrating that patients with ER+/HER-
/LN- tumours and intermediate RS (11-25) do not benefit from adjuvant chemotherapy (HR 
= 1.08; 95% CI, 0.94 to 1.24; P=0.26, [Hormonal vs. combination therapy (Endocrine + 
chemotherapy)])242. The RS signature is the most common prognostic assays used in the 
United States for ER+ patients and is commercially known as Oncotype DX. 
 
4.2.2 PAM50 (Prosigna) 
 
The PAM50 signature was generated using a qRT-PCR protocol that classifies 
tumours into five intrinsic subtypes and is comprised of 50 cancer-related genes. Detailed 
information regarding intrinsic subtypes and development of PAM50 signature are 
provided in section 2.7.  Parker et al. made a supervised continuous risk of relapse (ROR) 
score based on the PAM50 signature. ROR models were generated using 
clinicopathological characteristic of the tumours along with predefined variables to 
optimize the score90. These models include ROR-S, ROR-P and ROR-C.  
ROR-S: is developed by incorporating a Pearson correlation score comparing the 
expression of genes in test samples with the expression level of prototypical genes included 
in PAM50 intrinsic subtypes. ROR-S was initially tested on a training set of 189 breast 
cancer samples and the risk models were trained independently on the Netherlands Cancer 
Institute (NKI) dataset with 141 LN-, untreated patients90. ROR-P: is generated by 
combining the ROR-S with a proliferation score derived from the expression of 
proliferation genes included in the PAM50 signature. ROR-P has been shown to have 
greater prognostic strength compared to standard clinical variables in a cohort with ER+ 
patients who received hormonal treatment243. ROR-C: is made by combining ROR-S and 
the tumour size90.   
The prognostic value and clinical impact of the PAM50 signature and ROR models have 
also been compared to other signatures91, 243–246 where ROR provided more prognostic 
information than RS in ER+/LN- patients who received hormonal therapy244. Additionally, 
the ROR score added prognostic information to the Clinical Treatment Score (CTS) and 




ProSigna is an FDA approved commercial assay that adapted the PAM50 signature using 
the NanoString nCounter Dx system to generate risk models for cancer patients. The 
Prosigna ROR score ranges between 0-100 indicating the probability of distance recurrence 
in patients. The Prosigna ROR score has been shown to be able to predict early and late 
recurrences in a clinical trial setting244, 247, 248. This test is strongly recommended for use as 
an additional guide on making treatment decisions only for breast cancer patients with 
luminal LN- tumours249. According to the Nanostring technologies, Inc. the Prosigna assay 
is not suitable to use for LN+ patients with more than 4 lymph nodes involved250. 
 
4.2.3 Cell cycle score 
 
The prognostic value of gene expression signatures tends to rely heavily on genes 
associated with the cell cycle and proliferation251–253. Thus, the cell cycle score signature 
(CCS) was constructed on this notion: to reflect cell cycle activity of breast cancer tumours 
by employing genes that are directly involved in cell cycle progression225. A list of 463 cell 
cycle genes was assembled using the HUGO gene nomenclature company (HGNC), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) and Cyclebase databases254–256. CCS 
classifies tumours into three risk groups of low, intermediate and high cell cycle activity in 
which the latter group has the shortest BCSS relative to the low and intermediate group225. 
 
4.2.4 Breast cancer Index 
 
The Breast Cancer Index (BCI) is another gene expression assay based on a RT-
PCR method using FFPE samples performed by a central laboratory257. The BCI signature 
predicts distance recurrences in early stage breast cancer patients with ER+/LN- or LN+ 
tumours (1-3 nodes involved). BCI is developed by incorporating the expression of 5 genes 
associated with proliferation (BUB1B, CENPA, NEK2, RACGAP1, RRM2), 4 housekeeping 
genes (ACTB, HMBS, SDHA, and UBC) and a ratio between two genes (HOXB13 and 
IL17BR)258. The HOXB13 and IL17BR genes have been shown to be prognostic biomarkers 
in untreated or early-stage breast cancer patients who have received endocrine therapy257, 
258.  
The prognostic power of BCI to predict response to extended hormonal therapy has been 
demonstrated in previous studies where this signature has the ability to predict late distance 
recurrences in breast cancer patients258. BCI has outperformed Oncotype DX and IHC 
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markers in predicting a late distance recurrences259. Additionally, BCI can identify ER+ 





Endopredict is another prognostic multivariate assay based on qRT-PCR; it is used 
to predict late distance recurrences in early stage ER+/LN- breast cancer patients who have 
been treated with Tamoxifen261. The Endopredict assay is applied, by using the expression 
level of 8 cancer related genes (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, 
and STC2) and 3 reference genes (CALM2, OAZ1 and RPL37A). The combination of 
aforementioned genes, tumour size and LN status of the tumour generate a score calls 
EPclin. EPclin categorizes patients into low (EP score < 3.3 – lower than 10% of risk) and 
high risk (EPclin ≥ 3.3 – higher than 10% of risk) of distance recurrence within 10 years 
after diagnosis261, 262. The Endopredict signature outperformed common clinical parameters 
in terms of prognosis in both early and late distance recurrences in two adjuvant phase III 
clinical trials (ABCSG6 and ABCSG8) with ER+/HER2- patients who have been treated 
only with the endocrine therapy262.  EPclin score has been proven to be a superior 
prognostic signature compared to the ROR-C and ROR-PT (ROR-P in combination with 
tumour size) score tested in a randomized phased III trial263. Buus et al. compared the 
prognostic strength of EPclin and EndoPredict with RS using Likelihood ratio test (LRχ2) 
in which both Endopredict and EPclin score outperformed the RS (LRχ2: EP = 49.3; LRχ2: 
EPclin = 139.3; LRχ2: RS = 29.1)264.  
 
 PROGNOSTIC CLASSIFICATION OF BREAST TUMOURS (KI67 VS GENE 
SIGNATURES) 
 
It has been shown that Ki67 measured by IHC can provide similar prognostic information 
as bivariate gene expression signatures265. Additionally, Ki67 and bivariate gene signatures 
have been reported to retain high correlation in terms of prognostic classification of breast 
tumours265–267. However, this correlation decreased when similar comparisons were 





5 PAN-CANCER ATLAS 
 
High-throughput platforms and multiple omics approaches are incorporated into the 
routine cancer research resulting a large amount of biological and clinical data. Vast 
resources have been put into initiating cancer projects to exploit these data derived from a 
large number of tumour samples at DNA, RNA, Protein and epigenetic levels. The Cancer 
Genome Atlas (TCGA) Research Network was initiated by the National Institute of Health 
(NIH) in 2005 with the aim of exploring genomic alterations in human cancers. 
Subsequently, a large number of systemic cancer genomic projects have been conducted by 
TCGA starting with glioblastoma, ovarian and breast cancers270–272.TCGA projects have 
helped to identify novel oncogenes, biomarkers, cellular pathways and molecular subtypes 
with significant clinical implications270, 272–275.  
In 2013, TCGA announced a report from the first Pan-Can analysis project in which 
investigators have explored 12 different tumour types276 in 6 different genomic, proteomic, 
transcriptomics and epigenomics platforms. 
In a continuation of the first Pan-Can project, TCGA in collaboration with NIH and 
National Human Genome Research Institute (NHGRI) initiated a new Pan-Can Atlas 
project to study more than 11,000 samples across 33 cancer types (PanCan33) in similar 
platforms as the initial PanCan project in addition to whole genome sequencing and protein 
expression analysis. PanCan33 projects were conducted to extensively study cancer at a 
molecular level277 by investigating the role of genetic variants and mutational loads in a 
variety of tumour types278 and identifying signaling pathways involved in malignant 
transformation and cancer progression279; the tumour types studied in PanCan33 are Acute 
Myeloid Leukemia (LAML), Adrenocortical carcinoma (ACC), Bladder Urothelial 
Carcinoma (BLCA), Brain Lower Grade Glioma (LGG), Breast invasive carcinoma 
(BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), 
Cholangiocarcinoma (CHOL), Chronic Myelogenous Leukemia (LCML), Colon 
adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Glioblastoma multiforme 
(GBM), Head and Neck squamous cell carcinoma (HNSC), Kidney Chromophobe (KICH), 
Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), 
Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous 
cell carcinoma (LUSC), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), 
Mesothelioma (MESO), Ovarian serous cystadenocarcinoma (OV), Pancreatic 
adenocarcinoma (PAAD), Pheochromocytoma and Paraganglioma (PCPG), Prostate 
adenocarcinoma (PRAD), Rectum adenocarcinoma (READ), Sarcoma (SARC), Skin 
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Cutaneous Melanoma (SKCM), Stomach adenocarcinoma (STAD), Testicular Germ Cell 
Tumors (TGCT), Thymoma (THYM), Thyroid carcinoma (THCA), Uterine 
Carcinosarcoma (UCS), Uterine Corpus Endometrial Carcinoma (UCEC) and Uveal 


































AIM OF THE THESIS 
 
 
Study I: To examine if combination of Ki67 or IHC markers with gene expression 
signatures could provide more prognostic information than either of classifier alone. 
 
Study II: To assess the ability of clinically relevant gene expression signatures to predict 
post-relapse survival in biopsies taken from MBC patients.    
 
Study III: To clarify the prognostic and predictive capacity of CCND1 gene amplification 
in breast cancer patients through long-term survival analysis. 
 
Study IV: To explore the gene expression, DNA mutation and chromosomal arm-level 
alterations across and among PanCan Altas tumours with low, intermediate and high levels 






























6 PATIENTS AND METHODS 
 DATA COLLECTION  
 
Study I: Cohort 1: ER, PR, LN status and tumour size information of primary breast 
tumours were collected from the pathology reports. HER2 and Ki67 status were assessed on 
tissues microarrays (TMA) using chromogenic in situ hybridization (CISH) and MIB1 
antigen, respectively. The gene expression microarrays data were obtained from Gene 
Expression Omnibus (GEO)280 under the accession number of GSE48091.  
Cohort 2: Clinicopathological information was derived from the patient records and routine 
clinical measurements at the time of diagnosis. ER and PR status were collected using 
biochemical assays. HER2 and Ki67 status were assessed on whole tumour sections. 
Tumour grades were derived from the pathology report based on the Elston-Ellis grading 
system. The gene expression microarray data can be retrieved from GEO under accession 
number of GSE3494. Survival data for both cohorts were retrieved from the Stockholm-
Gotland Breast cancer registry and Socialstyrelsen42.  
 
Study II: All gene expression data were produced using on the Rosetta/Merck Human 
RSTA Custom Affymetrix 2.0 microarray166. The gene expression microarray data are 
available on GEO under accession number GSE56493.  
 
Study III: Cohort 1: The genomic and clinical data for this cohort (known as the 
METABRIC cohort) including, Hr and HER2 receptor status of the tumours, normalized 
copy number variation (CNV) and PAM50 molecular subtypes as well as normalized 
microarray gene expression data were taken from the online repositories accessible at 
European Genome-Phenome Archive (EGA) database281, and are available for research 
purposes.  
Cohort 2: is the same as Cohort 1 of Study I. 
 
Study IV: Data from the PanCan33 was used in this study. The mRNA, sequencing data, 
mutational and chromosomal arm-level alteration data as well as tumour aneuploidy scores 
were downloaded from the NIH genomic data commons database. All data is anonymized 
and is freely available for all to use for research purposes282. 
 
All gene expression studies included in this thesis were approved by the ethics committee at 
Karoliniska Institutet (Stockholm, Sweden). 
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 PATIENT COHORTS 
6.2.1 Merck Cohort 
 
The Merck cohort consists of 621 patients (768 study subjects) who were diagnosed 
with primary breast cancer in Sweden from January 1st 1997 to December 31st 2005 in the 
Stockholm health care area. This cohort was built upon a nested case-control design where 
the patients who were developed distant metastatic disease under the study period were 
selected as cases and the patients free from metastatic spread during the same period of 
time, were selected as controls. Then, the controls were randomly matched to each case in 
the following fashion: assigned to adjuvant treatment including chemotherapy, hormonal 
therapy or a combined treatment; the age of patients at primary breast cancer diagnosis 
were divided into (<45 years of age, 45-54 years, and >55 years).  
The median follow-up of Merck cohort is 14.4 years until January 10th 2015. The Merck 
cohort was used in Study I (as Cohort 1) and Study III (as Cohort 2). However, the nested 
case-control design of this cohort was ignored in both studies and the individual patient 
data were included instead. The exclusion reasons for each study were as follows: Study I: 
Of total 621 number of patients in the cohort, 379 were included in the analysis. The 
reasons for exclusions were: bilateral tumours (n = 2), unclassified tumours (n = 13), 
missing ER (n = 13), PR (n = 147), HER2 (n = 96) and Ki67 information (n = 55). Study 
III: From original 621 number of patients, 340 were included in the analysis. The 
exclusions were due to: bilateral tumours (n = 2), unclassified tumours (n = 14, ER-
/PR+/HER2- tumours), no matching SNP array (n = 68) and missing clinicopathological 
characteristics information (n = 197). 
 
6.2.2 Uppsala Cohort 
 
This cohort contains 468 patients with invasive breast cancer tumours who were treated 
with primary therapy in the Uppsala region of Sweden between January 1987 to December 
31 1989. The age of patients was between 28 and 94 years. A subset of 97 patients had LN+ 
metastases who received systemic adjuvant therapy. Premenopausal women received 
chemotherapy whereas the postmenopausal patients received hormonal treatment. Median 
BCSS in this cohort was 12.5 years. The Uppsala cohort was used in Study I (as Cohort 2).  
The exclusion reasons for the patients’ population in this study are as stated below:  
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Patients were excluded due to missing gene expression microarray information and lack of 
fresh frozen material (n = 251) as well as unclassified tumours (n = 24). 
 
6.2.3 TEX Cohort 
 
The TEX cohort, used in Study II is a Swedish multicentral randomized phase III 
trial where the combination of Epirubicin and Paclitaxel with/without Capecitabine were 
offered as a first line treatment.  A total number of 304 patients with loco-regional 
advanced or metastatic breast tumours participated in the trial under a period of 5 years 
(December 2002 to June 2007). Tumour biopsies were taken from the most accessible 
metastatic site by Fine-needle aspiration (FNA). RNA was extracted from these samples for 
expression array profiling. The gene-expression array data from whole genome of 109 
patients with complete follow-up were available at the end of TEX trial283 and used for 
gene expression studies.  
The reasons for exclusions in Study II were as follows: Of total number of 304 participants 
in the trial, 155 patients did not provide biopsies. 40 tumour biopsies did not pass the 
quality control. 4 biopsies classified as normal-like by PAM50 signature were excluded. 
The final inclusion was 105 samples in which 40 of them were LN biopsies and the rest of 
biopsies (n = 65) were taken from other metastatic sites.  
 
6.2.4 METABRIC Cohort 
 
Molecular Taxonomy and Breast Cancer International Consortium (METABRIC) cohort is 
a Canadian-British cohort consists of 1992 primary invasive breast cancer tumours. Only 
ER+/LN- patients received chemotherapy. Since this cohort study was initiated before 
approval of Trastuzumab, none of the HER2+ patients received anti-HER2 therapy284. 
DNA and RNA taken from samples were applied to Affymetrix SNP 6.0 and Illumina HT-
12 v3 platforms to obtain gene expression and mRNA expression profiling, respectively. 
Median follow-up for censoring was 10.2 years. Of the original 1992 patients of 
METABRIC cohort, 1965 were included in Study III (as Cohort 1).  
The reasons for exclusions were as follows: Duplicated samples (n=12) and unclassified 




6.2.5 PanCan Atlas  
 
The PanCan Atlas project has been described in section 5. Of the total number of 11,071 
patients in the PanCan33, 9,561 patients were included in Study IV (number of samples 
included in the study IV within each cancer type, ACC =  76,  BLCA = 398,  BRCA = 
1038, CESC = 291, CHOL = 36, COAD = 428, DLBC = 47, ESCA = 161,  GBM = 151, 
HNSC = 503,  KICH = 65,  KIRC = 481,  KIRP = 280,  LGG = 507, LIHC = 355,  LUAD 
= 498,  LUSC = 479, MESO = 81, OV = 289, PAAD = 158, PCPG = 160, PRAD = 471, 
READ = 154,  SARC = 242, SKCM = 458,  STAD = 404, TGCT = 133, THCA = 462, 
THYM = 103, UCEC =  514, UCS  = 56 and UVM = 80). The reasons for exclusions are 
missing clinical data (n = 797), missing gene expression data (n = 212) and unmatched 






The normalization of microarray data in Study I, Study II and Study III (Cohort 2) was 
done in R statistical software version 3.3.3285 using aroma.affymetrix package286. RMA 
method was chosen to normalize the data. The available data used in Study III (Cohort 1) 
has been normalized as described in the original study (supplemental information) using 
quantile normalization method284. The downloaded data used in Study IV (PanCan33) has 
been normalized as described in the original study277 using RNA-seq by Expectation 
(RSEM) method287.  
 
 
 STATISTICAL ANALYSIS 
 
All the statistical analyses in the studies were performed using R statistical software version 





6.4.1 Study I 
 
In this study, research versions of five gene signatures including PAM50, RS, GGI, CCS 
and 70-Gene signatures were tested in combination with Ki67 and IHC subtypes. The LRχ2 
test was used to calculate the additional prognostic information added by the gene 
signatures to Ki67 or IHC subtypes. The same test was used in the reverse analysis. Results 
from LRχ2 test can be seen as a goodness of fit of models which let us compare the 
combination of Ki67/IHC subtypes with the gene signatures. We used coxph package in R 
to assess the LRχ2 test with BCSS as clinical endpoint.   
 
6.4.2 Study II 
 
The same gene expression signatures (PAM50, RS, GGI, CCS and 70-Gene signatures) as 
in Study I were evaluated in this study. Kaplan-Meier (KM) and multivariate Cox 
regression analyses with the post-relapse BCSS survival as a clinical end-point were 
performed in this study using survival package in R. The multivariate models were adjusted 
for age at diagnosis, diagnosis date and treatment received in the study. The prognostic 
capacity of the gene signatures was evaluated using LRχ2 test.  
 
6.4.3 Study III 
 
Differences between clinicopathological variables and CCND1 amplified or non-amplified 
tumours, were evaluated using appropriate statistical tests based on the class of variables 
being compared. χ2 test was used when nominal variables were compared to nominal; 
Mann-Whitney test was used when ordinal variable was compared to nominal. The mean of 
gene expression of CCND1 amplified/non-amplified was tested within different PAM50 
subtypes using Student’s t-test. The Analysis of variance (ANOVA) test with post-hoc 
Tukey was chosen to perform a similar comparison for gene expression levels among 
PAM50 subtypes. Multivariate Cox regression models and KM analysis with BCSS were 
employed in this study and all multivariate models were adjusted for tumour size, tumour 
grade, LN status, hormonal therapy and PAM50 subtypes (Cohort 1 and 2). In the 
combined cohort, multivariate models were also adjusted for the cohorts included in the 




6.4.4 Study IV 
 
The same approach to Study III was taken to select appropriate statistical tests to assess 
differences among clinicopathological characteristics and inter-/intra-CCS subgroups. KM 
analysis was performed for inter-/intra-CCS subgroups. Due to the short follow-up time in 
the study, Progression Free Interval (PFI) was chosen as the clinical endpoint288. PFI is 
defined as the period during or after the treatment given to the patients in which the disease 
does not progress until loco-regional recurrences and/or other malignancies occur or the 
patients die from any cause. Multivariate Cox regression models were generated to evaluate 
the prognostic capacity of the inter- and intra-CCS subgroups. The multivariate models 
were adjusted for cancer types, age and gender of the patients, radiation therapy and 
pathological stage.  
 
 
 FURTHER ANALYSIS 
 
In the following sections, individual methods used in each study will be discussed.  
 
6.5.1 Study I 
6.5.1.1 Hormonal receptor, HER2 receptor and Ki67 status 
 
In Cohort 1, the ER and PR of tumours were collected from the pathological reports which 
was provided as a continuous variable. A ≥ 10 cut-off was used for the Hr positivity. Ki67, 
HER2 status were evaluated using MIB-1 antibody (1:100 dilution, DAKO) and CISH on 
TMAs, respectively. In Cohort 2, ER and PR were determined using ligand-binding assay. 
Ki67 expression was assessed by a pathologist at the invasive edge of a tumour and 
represented as a continuous variable. The same cut-offs as in Cohort 1 was used for the Hr 
positivity in Cohort 2. However, HER2 and Ki67 were evaluated on whole tumour sections 
in this cohort.  
 
6.5.1.2 IHC subtyping 
 
The IHC subtypes were generated using ER/PR/HER2 and Ki67 status of the tumours in 
the following manner: luminal A like: ER+ and PR+/- (considered as Hr+), HER2- and 
Ki67 low; luminal B like: Hr+, HER2-, Ki67 high; HER2+: Hr+/-, HER2+, Ki67 low/high; 
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and triple negative: Hr-, HER2-, Ki67 low/high. We chose the median value of Ki67 
expression from Cohort 1 (low and high, <16 and ≥16) as the Ki67 cut-off. 
 
6.5.2 Study III 
6.5.2.1 Hormonal receptor, HER2 receptor 
 
Cohort 1, ER and HER2 status of the tumours were taken from the clinicopathological data 
provided in the original study which were based on IHC. PR status was based on a gene 
expression classification as stated in the original report284. Cohort 2 of this study is the 
same as Cohort 1 in Study I (more information is provided in 6.5.1.1 section). 
 
6.5.2.2 Genome profiling 
 
Cohort 1, matched DNA and RNA extracted from patients were analysed using Illumina 
HT12-v3 platform and SNP arrays were run on Affymetrix microarray 6.0 platforms as 
described in the original study284. Cohort 2, RNA gene expression was carried out on 
customized HRSTA-2.0 Affymetrix array GPL10379225. DNA genotyping was performed 
on the Human1M-Duo BeadChip platform.  
 
6.5.2.3 Copy number analysis 
 
Cohort 1, data used in this study was downloaded from available online repositories as 
described in section 6.1 (Study III). Cohort 2, CNVs were generated using CNVpartition 
plugin within GenomeStudio software provided by Illumina (version 2011.1, Illumina, 
California, USA)289.  The Circular Binary Segmentation (CBS) algorithm290 was employed 
to generate CNV calls using DNAcopy291 package in R statistical program. We used the 
Genomic Identification of Significant Targets in Cancer 2.0 (GISTIC) module to generate 
Copy Number Alteration (CNA) for CCND1 gene in both cohorts. The GISTIC module 
gives an estimation about regions in the genome of samples that exhibit amplification and 
deletions. The G-Score provided in output of the algorithm shows the range and frequency 




6.5.3 Study IV 
6.5.3.1 Mutation analysis 
 
As described in section 6.1 (Study IV), all the data were derived from available online 
resources282. The mutational data was downloaded as a Mutational Annotation format 
(MAF) file. MAFtools293 package in R program was used to extract mutational counts 
within the PanCan33 dataset. Additionally, the mutational burden was calculated in the 
following manner: the total number of mutations divided by the total number of tumours 
within each cancer type to avoid biased analysis that would have been caused by a large 
number of mutations in a single cancer type.  
 
6.5.3.2 Chromosome arm-level alterations 
 
Aneuploidy score is a numeric value representing the alterations along chromosomal arms 
in which, values of +1, 0 and -1 represent the gains, non-aneuploidy and losses, 
respectively294. Tumour samples were divided into subgroups of amplified and deleted 
cases using the Aneuploidy score. The final counts for alterations were calculated by 
dividing the total number of losses/gains by the total number of tumours within each cancer 



















7 RESULTS AND DISCUSSIONS 
 STUDY I 
 
Comparable prognostic capacity of Ki67 measured by IHC and bivariate gene 
expression signatures has been demonstrated in several studies265–267. However, this 
correlation becomes weak between Ki67 and multivariate gene expression signatures since 
some tumour samples may be differentially classified using Ki67 or multivariate prognostic 
gene signatures265, respectively. Considering the discordance between tumours being 
classified as good prognosis by Ki67 or poor prognosis by multivariate gene expression 
signatures, we examined if the combination of Ki67/IHC subtypes, and the research version 
of gene expression signatures (GGI, 70-Gene, RS, CCS and PAM50) can provide more 
prognostic information than either classifier alone.  
This assessment was performed on four clinically relevant subgroups of patients including 
All patients (n = 379, n = 209), ER+/LN- (n = 104, n = 115), ER+/LN+ (n = 167, n = 65) 
and ER- patients (n = 103, n = 24) of Cohort 1 and 2, respectively. However, we expected 
to have more aggressive tumours in Cohort 1 due to its “nested case-control design” nature, 
as described in section 6.2.1. Notably, we observed approximately 14-22% (in Cohort 1) 
and 11-28% (in Cohort 2) discordance in tumour prognostic classification using Ki67 vs 
gene expression signatures.  
We took two approaches to examine our hypothesis using LRχ2 testing: First, we combined 
Ki67/IHC subtypes with gene expression signatures to evaluate additional prognostic 
capacity of the gene expression signatures beyond Ki67/IHC subtypes. Next, we reversed 
the combination and assessed the additional prognostic capacity of the Ki67/IHC subtypes 
beyond gene expression signatures. In all patients of Cohort 1, RS and PAM50 signatures 
provided statistically significant prognostic information beyond Ki67 (ΔLRχ2 RS = 12.8 
and PAM50 = 20.7; P = 0.001 and P < 0.001, respectively) and IHC subtypes (ΔLRχ2 RS 
= 12.9 and PAM50 = 11.7; P = 0.001 and P = 0.020, respectively). A similar trend was 
observed in the ER+/LN- subgroup. In the ER+/LN+ subgroup, all gene expression 
signatures added prognostic information beyond Ki67 and IHC subtypes. This may indicate 
that gene expression signatures can capture additional biological information in this 
subgroup of patients which was not provided by the clinical IHC markers. Moreover, all 
gene expression signatures lost their prognostic power in the ER- subgroup of patients.  
In the reverse analysis, IHC subtypes added prognostic information on the top of all gene 
expression signatures except PAM50 in All and ER- patients (All patients, PAM50/IHC 
subtypes ΔLRχ2 = 7.1, P = 0.068, ER- patients ΔLRχ2 = 2.1, P = 0.146), respectively. 
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Similar results were observed in Cohort 2 despite a lower number of patients compared to 
Cohort 1.  
The results from Study I showed the prognostic superiority of PAM50 signature compared 
to IHC subtypes. We have also shown that IHC subtypes can compete well against most of 
prognostic gene expression classifiers.  
 
 STUDY II 
 
Although gene expression signatures have been demonstrated to provide prognostic and 
treatment predictive information in primary breast tumours, their prognostic capacity has 
not been tested in MBC patients.  In Study II we explored the prognostic strength of some 
clinically relevant gene expression signatures in the metastatic setting.  
First, we tested the ability of GGI, 70-Gene, CCS and PAM50 gene expression signatures 
to predict post-relapse BCSS survival using KM and Cox regression analyses. Across all 
gene expression signatures, only PAM50 provided significant prognostic information when 
all metastatic sites were included in the analyses (univariate analysis, Short-term BCSS, 
HER2-enriched:HR = 3.0, 95% CI, 1.2 – 7.4, basal-like:HR = 3.2, 95% CI, 1.3 – 8.0, Long-
term BCSS, HER2-enriched:HR = 1.9; 95% CI, 1.1 – 3.4). Our results remained significant 
in multivariate analysis after adjusting our models for age at diagnosis, diagnosis date and 
clinical treatment received, in which luminal A subtype tumours had the best prognosis 
relative to luminal B, HER2-enriched and basal-like subtype tumours (Short-term BCSS, 
HER2-enriched:HR = 3.2, 95% CI, 1.3 – 7.9, basal-like:HR = 3.0, 95% CI, 1.2 – 7.5, Long-
term BCSS, HER2-enriched:HR = 1.9; 95% CI, 1.1 – 3.3). Next, we examined the 
capability of PAM50 gene expression signature to predict post-relapse from LN biopsies. In 
multivariate analyses basal-like and HER2-enriched (long-term BCSS) subtypes provided 
statistically significant information (Short-term BCSS, basal-like:HR = 2.6, 95% CI, 2.7 – 
247.5; Long-term BCSS, HER2-enriched:HR = 3.7; 95% CI, 1.2 – 11.6; basal-like:HR = 
7.9; 95% CI, 2.2 – 28.2).  
Finally, LRχ2 test was used to determine the capacity of gene expression signatures to 
provide prognostic information in MBC patients. The PAM50 was the only signature that 
provided prognostic information in the metastatic setting (LRχ2: long-term = 20.0 and 10.4; 
P < 0.001 and P = 0.015 in LN and Other metastatic sites, respectively). 
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In Study II, we showed that the majority of gene expression signatures classify metastatic 
tumours as poor prognosis. Notably, PAM50 can provide prognostic information from LN 
metastases in MBC patients. 
 
 STUDY III 
 
Several biomarkers have been identified that are capable of selecting breast cancer 
patients with poor long-term survival232, 265. Additionally, the clinical utility of gene 
expression signatures has been proven in recent studies225, 264.  
Cyclin D1 protein has been demonstrated to be overexpressed in more than half of breast 
cancer tumours in which higher level of cyclin D1 protein expression has been correlated to 
both good and poor prognosis36, 295–297. On the other hand, the amplification of its 
corresponding gene CCND1 has consistently been associated with poor prognosis in breast 
cancer patients36, 37, 298. In this study, we aimed to clarify the prognostic and predictive 
capacity of CCND1 gene amplification, thus promoting its use as a clinically relevant 
biomarker for long term BCSS. 
Twenty-two (426/1965 22%) and thirty-five percent of tumours in Cohort 1 and Cohort 
2(119/340, 35%) were found to be CCND1-amplified, respectively. A higher number of 
CCND1-amplified tumours was observed in the more aggressive Cohort 2.  In general, the 
majority of the CCND1-amplified tumours were ER+ or luminal subtype tumours relative 
to non-amplified tumours (Cohort 1 ER+ = 88% vs 73%, luminal A or B = 73% vs 58%, 
Amp/non-Amp, respectively).  
In Cohort 1, patients with CCND1-amplified tumours showed worse long-term BCSS in 
subgroups of ER+/LN-/HER2- and ER+/LN+/HER2- (log rank P < 0.001 and P = 0.016, 
respectively) as well as luminal A subtype tumours in addition to endocrine treated and 
untreated patients (log rank P = 0.019, 0.007 and 0.014, respectively). In the multivariate 
Cox regression analyses, the results remained statistically significant in ER+/LN-/HER2- 
subgroup (HR = 1.72, 95% CI, 1.14 – 2.59) with comparable trends for luminal A patients.  
We have observed similar results combining both cohorts 1 and 2. In the combined cohort, 
patients were found to have poorer 15-years BCSS in multivariate analysis (ER+/LN-
/HER2-, HR = 1.66, 95% CI, 1.14 – 2.41; luminal A, HR = 1.68, 95% CI, 1.15 – 2.46; 
luminal B, HR = 1.37, 95% CI, 1.01 – 1.86, respectively). These results highlight the 
prognostic potential of CCND1-amplification status to stratify patients with poorer 15-years 
BCSS survival. In the next step, the expression of genes related to the cell cycle and cell 
proliferation was examined within PAM50 subtypes in Cohort 1.  
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We demonstrated that luminal A/CCND1-Amplified tumours have higher expression of 
MKI67 (proliferation marker gene) and lower PGR expression relative to luminal A/non-
Amplified tumours; this could be the reason that luminal A/CCND1-Amplified tumours 
show poorer 15-years BCSS relative to luminal A/non-Amplified tumours since they show 
similar characteristics as more aggressive luminal B subtype tumours299.  
It has been previously suggested that CCND1-amplification could act as a biomarker for 
predicting patients who may respond to CDK 4/6 inhibitors6. Given that, we explored the 
expression of CDK4 and CDK6 genes within CCND1-amplfied and non-Amplified 
tumours; our data from the gene expression analysis implied that CCND1-amplification 
would perform poorly as a predictive biomarker in this setting which are in agreement with 
the findings of PALOMA-1/TRIO-18 randomised phase II trial showing patients with 
CCND1-amplified tumours do not benefit from the CDK4/6 inhibitor Palbociclib300.  
Finally, differential gene expression analysis was performed between CCND1-amplfieid 
and non-amplified tumours in luminal A and B subtypes, separately. Notably, these two 
PAM50 subtypes share common genes within CCND1-amplfied tumours. 
 
  
 STUDY IV 
 
Genomic alterations are main causes of loss of control over the cell cycle which is a 
hallmark of cancer2. In Study IV, we explored the genomic alterations including DNA 
mutations and chromosomal arm-level aneuploidy among and within tumours with low, 
intermediate and high cell cycle activity using the CCS signature225.  The chromosomal 
arm-level aneuploidy was derived from aneuploidy score294 which represents a total number 
of chromosomal changes at an arm-level in a given sample. 
We demonstrated that cell cycle activity varies a lot among cancer types with KICH, 
PCPG, KIRP and PRAD tumours exhibiting lowest and TGCT, DLBC, HNSC and CESC 
tumours highest level of cell activity among 33 cancer types. Furthermore, we examined 
DNA mutations of 299 well defined onco- and tumour suppressor driver genes in relation to 
cell cycle activity among (inter) and within each cancer type (intra)301. 
TP53 and PIK3CA had the highest mutation rate within subgroups of high and intermediate 
inter-CCS while KRAS and BRAF mutations were prominent in the low and intermediate 
inter-CCS. The intra-CCS subgroups were also dominated by TP53 and PIK3CA mutations 
in all subgroups of low, intermediate and high intra-CCS. BRAF mutations were among top 
15 genes with highest mutation rate in high intra-CCS. These observations imply that 
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mutations of the aforementioned genes are not only associated with highly proliferative 
cancers, despite their direct association with cell cycle progression21, 302. 
The finding from chromosomal arm-level gains/losses analyses showed that the aneuploidy 
score significantly increases with increasing cell cycle activity among cancers (inter-CCS) 
but not in intra-CCS level. Higher level of amplification was observed in chromosomes 7p, 
20q and 8q in the subgroups of inter/intra-CCS while the most frequent deletions were 
observed in 17q arm followed by 8p and 18q in the similar subgroups. Next, we assessed 
the PFI using KM analysis between inter- and intra-CCS groups. The inter-CCS had 
prognostic capacity whereby patients with low inter-CCS had longer PFI relative to 
intermediate or high inter-CCS groups (P < 0.001); while no difference in PFI was found 
between intra-CCS groups. Finally, inter-/intra-CCS were tested in multivariate Cox 
regression models. In multivariate analysis inter-CCS remained statistically significant after 
adjustments for tumour type, age, gender, pathological grade and radiotherapy 
























 STUDY I 
 
Our findings in this study indicate that RS and PAM50 signatures can provide more 
prognostic information compared to the IHC subtypes in all breast cancer patients. Notably, 
IHC subtypes did not add prognostic value to the PAM50 signature.  
 
 STUDY II 
 
We showed for the first time that PAM50 signature provides prognostic information when 
applied to LN metastases and could potentially be used in the metastatic setting to aid 
treatment decisions.   
 
 STUDY III 
 
We demonstrated that amplification of CCND1 is correlated with poorer 15-year BCSS 
survival in patients with ER+/LN-/HER2-, luminal A and luminal B subtype tumours. 
Furthermore, luminal A tumours exhibiting amplification of CCND1 have similar gene 
expression changes as tumours with a luminal B subtype. Our findings emphasize the 
potential of CCND1 amplification to be used as a biomarker to identify patients who may 
benefit from aggressive treatment strategies. 
 
 STUDY IV 
 
The results of this study indicate that DNA alterations are presented at all cell cycle activity 
levels, whilst some significant exceptions exist such as KRAS and BRAF mutations. We 
also demonstrated that cell cycle activity deviates extensively across and within cancers. 
Finally, our data show that a simple gene expression signature representing cell cycle 
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